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“The urge to miniaturize electronics did not exist before the space program. I 
mean our grandparents had radios that was furniture in the living room. 
Nobody at the time was saying, 'Gee, I want to carry that in my pocket.' Which is 
a non-thought.” - Neil deGrasse Tyson 
 
There are many reasons to believe that miniaturized microfluidic chip-based systems, which can 
perform most of the functions of laboratory technicians – will soon become a powerful tool in the 
effort to combat infectious disease in resource-limited settings. Just like integrated circuits that shrank 
and by so doing, democratized computing technology, microfluidics has the potential to bring the 
miracle of miniaturization to medical diagnostics and research. 
The work described in this project is an example of innovation in bring the power of miniaturization 
to the several microfluidic systems that are currently suffering from technological challenges that 
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In the same way that the HIV virus subdues the human immune system, the HIV/AIDS epidemic has 
severely overloaded the health service infrastructure in resource limited countries and threatens to 
systematically suppress societies’ capacity to cope with killer diseases. The epidemic has also directly 
impacted the health workforce, causing absenteeism, attrition (due to illness and death), and increased 
demand for provider time and skills. Advanced and miniaturized microfluidic systems can perform 
complex biotechnological functions such as growing bacteria, sequencing DNA and identifying 
disease causing pathogens. As a technology, microfluidics offers so many advantages but it also 
suffers from a variety of technological drawbacks that limit its wide spread practical application in 
hospitals and patient setting. Microfluidic systems require a lot of time (6 hours to an entire work-day) 
to set up and the set-up process requires the meticulous attention of highly trained personnel. We 
proposed the development of an automated, time conservative and user-friendly fluid-transport system 
(off-chip to on-chip) for Microfluidic Large Scale Integration platform based microfluidic devices. 
Using multilayer soft-lithography, micro-electric actuators and a LabVIEW graphical user-interface, a 
user-friendly automated microfluidic fluid transport system was developed. In comparison to the 
conventional manual loading system, the developed system can save at least 60% of the total chip 
preparation time required during the off-chip to on-chip fluid loading process. This system can be 
extended and made compatible with other devices that require complex off-chip to on-chip loading 
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CHAPTER 1: INTRODUCTION 
 
The growing demand within the global health community to find new and improved efficient medical 
diagnostic methods for HIV/AIDS and TB without diminishing the quality of patient care has led to 
the development of various point-of-care technologies. The emergence of microfluidics technology 
and the demand of point-of-care (POC) diagnostic solutions in the health care system stimulated an 
interest in further research and development of miniaturized laboratory equipment and processes with 
the capability of clinical diagnostics. 
Point-of-care technology for medical diagnostic testing has the possibility of bringing about improved 
health care service delivery in resource limited settings where there has been poor management of 
infectious diseases due to weak health care infrastructures that do not provide the necessary access to 
high-quality and timely medical care. POC technology offers rapid tests enabling ample time for 
initiating the appropriate treatment plan of action and provide medical decisions such as referrals 
without requiring fixed laboratory infrastructures. Developments in the microfabrication industry have 
allowed clinical diagnostics to be miniaturized for use in POC medical diagnostic testing. 
In the same way that cell phones shrink computer technology, microdevices shrink medical 
laboratories onto an iPhone sized cartridge. Microdevices, as a product of the various available 
microfabrication processes especially in the category of microelectromechanical systems (MEMS) or 
commonly referred to as lab-on-a-chip (LOC) systems can be composed by an integration of 
microchannels, microvalves, micropumps, microfilters and microelectronics and other mechanical and 
electrical components. The same fabrication processes such as photolithography and soft-lithography 
used in the electronics industry brought about the establishment of what has become the potentially 
suited and the core technology used in the fabrication of microdevices for clinical diagnostics. This 
rising technological platform is Microfluidic Large Scale Integration (MLSI). 
Microfluidic large scale integration refers to the development of microfluidic chips with thousands of 
integrated microvalves and fluidic control modules [1]. Basically, microfluidics is the science and 
technology of systems that process or manipulate small amounts of fluids (micro- to nano-liters), 
using channels with dimensions of tens to hundreds of micrometres [2]. MLSI is a microfluidic 
platform that specifically uses an extension of soft-lithography microfabrication process developed by 
the Quake group in the early 2000s called Multilayer Soft-Lithography (MSL) [3]. MLSI technology 
can only be created in a highly maintained and equipped clean room facility. A clean room is a 
specially designed laboratory where the size and the number of airborne particulates are highly 




Analogous to the manner at which computer viruses and malware affect the operating system of a 
computer, and the way that the HIV virus subdues the human immune system, the HIV/AIDS 
epidemic has severely overloaded the health service infrastructure in resource limited countries and 
threatens to systematically suppress societies’ capacity to cope with killer diseases. One approach that 
addresses challenges in the health care systems in resource limited countries is research and 
development of new POC technologies.  
Many have expressed doubts that today’s global health system is remotely adequate for meeting the 
emerging challenges of the 21st century [5]. A groundswell of opinion suggests that a new way of 
thinking is needed to improve the global health systems’ ability to deal with the emerging challenges 
and one such way is by ensuring sufficient long-term investment in health research and development 
[5]. We, as part of the health research and development industry are expectant of an era of powerful, 
low cost, portable point-of-care (POC) diagnostic devices that will help combat infectious diseases in 
South Africa as well as in sub-Saharan Africa as a whole where these diseases progress the most. This 
is where Microfluidic Large Scale Integration (MLSI) microfluidic systems come into effect. 
Development of advanced and miniaturized microfluidic systems that can perform complex 
biotechnological functions such as growing bacteria, sequencing DNA and identifying disease causing 
germs under the automated control of a multi-tasking computer with minimal human involvement will 
thereby provide the ultimate low cost, portable POC medical diagnostics tools. 
Microfluidic large scale integration technology offers many advantages making it a possible suitable 
platform to develop POC clinical diagnostic tools that specifically address the barriers existing in the 
health care delivery systems in resource limited countries. Just like integrated circuits that shrank and 
by doing so, democratized computing technology, microfluidics has the potential to bring the miracle 
of miniaturization to medical diagnostics and research. For example: 
 The ability to combine patient sample preparation and analysis processes onto a single, 
integrated microfluidic device creates benefits such as the need for less sample (therefore less 
time needed to grow-up microbes and less risk of exposure to infectious doses of pathogens); 
less reagents (therefore lower cost); automation (therefore minimal human labour costs); and 
small size (possible portability). 
 The self-contained nature of microfluidic systems is ideal for clinical analysis and research, 
especially when technologists need to be insulated from the potentially hazardous pathogens 
such as HIV and Mycobacterium Tuberculosis (MTB). 
 Automation – performance of complex biological tasks hitherto done by humans. Particularly, 
the microfluidic approach can multiply the output of clinical technologists by allowing them 
to perform hundreds or thousands of tests simultaneously on a single microfluidic chip 




Scope of Dissertation 
 
The ultimate goal of the work presented in this dissertation is the design, development and 
characterization of a portable, automated fluid transport system for the microfluidic large scale 
integration platform. 
To highlight the importance of developing such systems, Chapter 2 presents the literature available 
on the effect of HIV and TB on the health care infrastructure, the available point-of-care diagnostics 
methods and instrumentation and the unmet needs of point-of-care diagnostic testing in resource 
limited settings. This chapter also introduces microfluidics technology, the underlying principle and 
the critical components that make on-chip automation possible. The importance of research and 
development in new medical diagnostics which meet the necessary requirements for point-of-care 
testing in resource limited settings is also discussed. The chapter also presents the promise of 
microfluidic large scale integration systems. 
Chapter 3 describes the research aims and objectives. The conceptual framework to achieve the 
project goals is presented at the end of this chapter. 
Chapter 4 presents the methodology. The methodology presented involves the fabrication methods 
and protocols followed in developing the microfluidic devices. This chapter also states the 
development of a one-of-a-kind microfluidic plug. It also presents the user-friendly developed 
graphical user operating system for off-chip to on-chip automation. 
Chapter 5 presents the results, analysis and discussion. In this chapter the developed automated fluid 
transport systems are described and the systems’ strengths and weaknesses are analysed and 
discussed. Each system designed after the initial design was developed as a solution to the identified 
problems in achieving a complete, automated off-chip to on-chip fluid transport system. 
Chapter 6 presents the conclusion. This chapter will provide a summary of the results obtained and 
how this system can be improved. 
Chapter 7 presents the future work. In this chapter, proposed solutions to the final system developed 
will be recommended. These recommendations aim to eliminate some design flaws identified during 
the development, and also enhance the efficiency of the system in automating the fluid transportation. 






CHAPTER 2: LITERATURE REVIEW 
 
2.1 Background and Significance. 
 
Sub-Saharan Africa, is characterized as the region with the heaviest burden of disease as a result of 
poor health care systems, limited resources and inadequate skilled clinical personnel [6]. In 2010, as 
shown by Figure 2.1 (a), 12 % of the world’s population resided in sub-Saharan Africa.  
According to World Health Organization (WHO) statistics, represented by Figure 2.1 (b) and Figure 
2.2 (a), in 2010 there were about 9.2 million doctors and 18.1 million nurses worldwide. Of all the 
regions in the world, sub-Saharan Africa has the least number of doctors and nurses yet it has the 
largest disease burden. A more revealing statistic of the inadequacy of health care personnel in sub-
Saharan Africa is illustrated using Figure 2.2 (b), which shows the doctor and nurse density per 1000 
of the population, and it shows that sub-Saharan Africa region has the least doctors and nurse density 
per 1000 people of the population. Using the data presented in Figure 2.1 and Figure 2.2, it can be 
seen that, regions like the Americas and Europe have a better health workforce capable of handling 
their population whereas regions like South East Asia and sub-Saharan Africa do not have enough 
doctors and nurses to provide adequate health care to their people. 
Unfortunately, the inadequacy of the health workforce in sub-Saharan Africa is further worsened by 
the current state of affairs and challenges such as poverty, famine, infrastructure decay, political 
instability and other debilitating diseases [6, 7]. 
With critical shortages of health personnel in the health care sector in sub-Saharan Africa, it is 
important to determine the impact of epidemics such as Human Immunodeficiency Virus (HIV) and 











Figure 2.1: (a) Pie chart showing the distribution of the world’s population per region in 2010; 
(b) Pie chart of the number of doctors in each of the regions in 2010. The data was obtained 
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Figure 2.2: (a) Pie chart showing the distribution of the nurses in the world’s population 
according to region in 2010; (b) Pie chart showing the doctors and nurse density in each of the 
regions in 2010. The data was obtained from References [8] and [9]. 
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2.1.1 The Impact of HIV/AIDS, Tuberculosis on the Health Service 
Infrastructure and the Health Workforce in Sub-Saharan Africa.  
 
In the same way the Human Immunodeficiency Virus (HIV) virus prior the stage of Acquired Immune 
Deficiency Syndrome (AIDS) subdues the human immune system, the HIV epidemic has severely 
overloaded the health service infrastructure in resource limited countries and threatens to 
systematically suppress the societies’ capacity to cope with the killer diseases.  
Before the emergence of the HIV/AIDS pandemic, health systems in sub-Saharan Africa were 
progressively improving the general health status of the populace [10]. The steady improvement of the 
health service delivery was accredited to the quality and increased access to various health services in 
an era with ‘manageable’ diseases. When HIV/AIDS arrived on the global scene, there was a 
substantial increase in the demand for health services in the populace. The worst hit regions were the 
low and middle income countries. In 2013, an estimated 35 million people were living with HIV 
worldwide [11]. Sub-Saharan Africa, which consists of most low and middle income countries, had 
approximately two thirds (24.7 million) of the people living with HIV [11, 12]. 
By bringing about the resurgence of previously well controlled diseases such as tuberculosis, 
malnutrition, diarrhoea and other opportunistic infections, their prevalence has increased due to 
HIV/AIDS which led to a shift in the status quo of human health, disease and health care delivery 
systems [10]. One of the resurgent diseases is tuberculosis (TB) and its most threatening strains, 
Multidrug Resistant Tuberculosis (MDR-TB) and Extensively Drug Resistant tuberculosis (XDR-
TB), is being ranked as one of the deadliest communicable disease. In 2013, an estimated 9 million 
people developed TB worldwide and about a quarter of those where people in Africa [13]. TB remains 
the leading cause of death in people living with HIV, with an estimated 360 000 deaths in 2013 [13]. 
Most TB deaths are preventable (especially for health care givers who come into contact with these 
patients), however, the death tolls are still unacceptably high and efforts are being put into place to 
reduce it within the contexts of the Millennium Development Goals (MDGs). 
The health workforce is at risk of many infections at the workplace through airborne, blood borne, 
faecal-oral transmission and direct contact [14]. The emergence of HIV on the global scene increased 
the attention of the high risks of exposure the health workforce face to blood borne pathogens. The 
two disease synergy, HIV and TB has led to the overcrowding of available health facilities and little is 
known about the impact these epidemics have had on the health care workers [15]. This synergy and 
other infections have also directly impacted on the health workforce. The co-existence of HIV (blood 
borne pathogen) and TB (airborne pathogen) poses a threat to the already under-equipped health care 




diseases. Blood borne pathogens may be transmitted through percutaneous (contact with intact or non-
intact skin) or mucocutaneous (contact with mucous membranes) and exposure to other body fluids 
[14]. Airborne pathogens can be transmitted through inhalation of pathogens that travel on dust 
particles or small respiratory droplets that become aerosolized when people sneeze, cough, laugh or 
exhale. One of the ways health workers get TB infections is through airborne transmission of 
aerosolized respiratory droplets created by TB patients when they cough and sneeze. 
For successful implementation of health reforms such as prevention and treatment approaches, the 
human resource (health staff) need to compliment the health services. The increased disease burden in 
the low and middle income countries has a negative impact on the morale and job satisfaction of 
health workers [16], thus the balance between health care service delivery and the available health 
workforce  has not been met. 
Case studies evidently show that most HIV/AIDS and TB patients seek health care services in public 
hospitals at an advanced stage of illness resulting in the high inpatient death rates combined with the 
limited health care service deliverables such as diagnostic tools, medication, counselling has 
contributed to the increased professional demoralization, absenteeism and reduced productivity on the 
human resource [10, 16].  In many resource limited countries, the working conditions of the health 
workers has been characterized by poor salary and wage bills resulting in the migration of 
professionals to greener pastures further impacting negatively on the health care system [16]. For rural 
areas in these resource limited countries, they lack the access to the requisite technology and the 
necessary trained personnel to perform the diagnostic tests and carry out the subsequent diagnoses, 
especially where the situation is complicated for patients with multiple concomitant infection and 
malnutrition [17]. In South Africa, it is reported that health workers experience stress, fear, frustration 
and depression due to their contact with patients living with HIV/AIDS and some limitations of their 
work environments [18]. Care of dependents and funeral attendance amongst health workers attribute 
to the increased absenteeism. Reports suggest that an average person can be absent from work fifty 
(50) percent of their final year of life once they develop AIDS [10]. For example in the case of 
Botswana in 2003, if an average person was to use just sixty (60) days and six (6) months of sick 
leave in their last year, the public health sector could have lost around 23 000 and 42 500 work days 
respectively to AIDS amongst its health workforce [10]. This study showed the significance of the 
health workforce in the public health care sector.  
Another example of the impact of HIV/AIDS, TB and other opportunistic diseases on the health 
workforce was in the year 2000, where an estimated 66 000 hepatitis B (HBV), 16 000 hepatitis C 
(HCV) and 1 000  HIV infections occurred worldwide amongst the health care workers due to 




The global community has introduced improved health reforms that reduce the impact of HIV/AIDS, 
TB and other opportunistic infections on the health workforce [15]. There has been an increase in 
safer nursing and surgical techniques [16] and improvements in waste disposal, especially with 
needles and increased awareness’ of occupational post exposure prophylaxis (o-PEP) providing 
adequate barriers that help prevent the health workers from being infected at the workplace [14]. 
One suggestion to address the negative impact of the co-epidemics of HIV and TB on the health 
workforce is the improvisation of already existing diagnostic devices available on the market. An 
increased investment into new research and development of latest medical diagnostic devices can 
provide economically viable point-of-care diagnostics. A positive outcome of the successful 
implementation of these suggestions is the research and development of POC diagnostics that 
adequately protect the health workforce thus reducing occupational risks of exposure to infectious 
pathogens. 
This credits a need to understand what point-of-care (POC) medical diagnostics is and how they 
address the impact of the co-epidemics of HIV and TB on the public health care sector and its 
workforce. 
2.2 Current Point-of-Care Diagnostics for HIV/AIDS and TB.  
 
In consideration of the following factors such as:  
i. Sub-Saharan Africa has the heaviest disease burden. 
ii. Sub-Saharan Africa has a critical shortage of health personnel. 
Sub-Saharan Africa health care service delivery systems are poorly equipped to contend with 
emerging health care threats such as HIV, TB, Ebola and other opportunistic infections. Typical 
conditions in a mid-level health care centre in resource limited settings such as those found in sub-
Saharan Africa are rather different from those in a developed-world mid-level clinical laboratory [19].  
Sources of running water and electricity may or may not be available, with power being at best 
sporadic with wide fluctuations in voltage [19]. Dust, wind and contaminating pathogens are very 
common coupled by ambient temperatures that range from 10 ºC to more than 40 ºC [19]. Potentially 
high-risk human samples, containing biosafety level (BSL) -2 and BSL-3 pathogens are casually 
handled with few to none precautious taken except using gloves [19]. With such conditions in place, it 
is still possible to perform microscopy, most lateral flow assays, some blood chemistry, cytology and 
enzyme-linked immunosorbent assays (ELISAs) in these mid-level health care centres [19]. With 
stretched and scarce medical professionals, limited resources and heavy disease burden, low-cost 
point-of-care (POC) tests have transformed the management of several major infections such as HIV, 




testing device used in hematology for obtaining white cell counts, Daktari CD4 system (Daktari 
Diagnostics Inc., USA); a POC device used for CD4 cell counting in HIV/AIDS management, Xpert 
MTB/RIF (Cepheid, USA); a POC device used to simultaneously detect mycobacterium tuberculosis 
(MTB) and rifampin (RIF) resistance by Polymerase Chain Reaction (PCR) amplification in TB 
diagnostic testing and the VIKIA® Malaria Ag Pf/Pan (BioMérieux/IMAccess, France); an 
immunochromatographic technology based POC test for malaria diagnostic testing. 
 
Point-of-Care (POC) testing is the laboratory diagnostic testing performed outside the well-controlled 
environment of the traditional, physical facilities of the clinical laboratories near the clinical care 
delivery site [21]. The medical diagnostic tools and techniques used in such an environment are called 
POC diagnostics. 
POC tests are designed in such a way that they are simple enough to use at the primary care level in 
remote and resource limited settings with no laboratory infrastructures. POC tests are often cost-
effective for both developed and developing nations to complement their health care delivery systems 
[22].  
2.2.1 HIV POC Diagnostics and the Need for Portable, Automated, Cost 
Effective, High Volume and Rapid Sample Processing Diagnostic Systems. 
 
The HIV health care service delivery includes a spectrum of services such as diagnosis, treatment, 
monitoring and support. The HIV diagnosis sub-spectrum involves the HIV testing (for adults and 
children), early infant (younger than 18 months) diagnosis (EID), disease staging, and treatment, 
monitoring and drug resistance assay [6]. 
HIV initial tests include HIV antibody tests (measured in blood, saliva or urine), p24 antigen tests and 
polymerase chain reaction (PCR) tests [23]. Amongst these tests, HIV antibody tests are most 
commonly used for routine diagnosis and HIV rapid disposable tests which use blood or saliva are 
most commonly used for screening at point-of-care for patients older than 18 months of age [23].  For 
EID, PCR based tests are performed on HIV-infected and HIV-exposed infants and are most 
commonly used in programs that provide prevention of mother-to-child transmission (PMTCT) 
services. Confirmatory tests of the diagnosis, when patient tests positive for HIV are also performed 
using rapid disposable tests and this is the common practice in resource limited settings. In other 
settings the confirmatory tests include the use of an enzyme-linked immunosorbent assay (ELISA) at 
point-of-care or a Western Blot and Radio Immunoprecipitation Assay (RIPA) which are conducted in 




Table 2.1, is a summary of the available HIV diagnostic tests being used by health systems. Most 
serological tests are POC and enzyme immunoassay-based methods thus most of the POC diagnostic 
tools that use these methods are immunochromatographic-lateral flow devices [6].  
Immunochromatographic-lateral flow devices also commonly referred to as ‘sol particle immunoassay 
(SPIA)’ [24], ‘immunochromaticgraphic strip (ICS)’ [25], ‘test strip’ or ‘immunocapillary tests’ are 
all lateral flow tests (LAT) tests that fall under the ‘Capillary’ microfluidic platform. In lateral flow 
tests, the liquids are driven by capillary forces where liquid movement is controlled by the wettability 
and feature size of the porous or microstructured  substrate [26]. A basic necessity of these tests is that 
all the required chemicals for the reaction should be pre-stored within the strip beforehand, and once 
the test is performed, the readout is usually optically visible to the naked eye and this is often 
implemented as a colour change in the detection area [26]. A LAT device is comprised of an inlet port 
and a detection window. Within the device is the core made up of several pre-stored wettable 
materials that provide the biochemicals and capillary capacity to drive the sample through the core 
during the test. A sample is introduced into the device via the inlet port and onto a sample pad which 
holds back contaminations and dust [26]. Through capillary action, the sample is transported into the 
conjugate pad, where antibodies conjugated onto a signal-generating particle are rehydrated and bind 
to the antigens in the sample [26]. The binding reaction is repeated as the sample flows into the 
incubation and detection pad where on the first line (referred to as the control line) a second type of 
antibody catches the particles coated with antigens and in the event that there are particles that did not 
bind to an analyte in the first test line; these are caught by a third type of antibodies. Typically, for 
lateral flow devices, in the detection window, the first control line shows a successful processed test, 
while the second line (referred to as the test line) shows the presence or absence of a specific analyte 
[25, 26]. Examples of immunochromatographic-lateral flow devices are, the OraQuick ADVANCE® 
Rapid HIV-1/2 Antibody Test [27], Reveal G3 Rapid HIV-1 Antibody Test (Reveal G3) [28] and the 
Uni-Gold™ Recombigen HIV [29]. 
Typically, some of the advantages offered by serological POC diagnostic tools are: 
i. Rapid: - quick turnaround time to obtain results, usually within minutes. 
ii. Cost effective: - the tools make the test inexpensive and affordable. 
iii. High sensitivity: - they have a good sensitivity, for example, ELISA commercial kits have a 







Table 2.1: HIV-1 and HIV-2 Diagnostic Testing and Monitoring Landscape obtained from 
Reference [25]. For example, many POC serological tests and enzyme immunoassay-based 
methods use immunechromatographic-lateral flow devices even though specificity is a limitation 
on these tests. Most of the HIV-1 antibody screening assays have more patient approval because 
of their non-invasive nature. 
TEST Examples 
HIV-1 Antibody Screening Assays 1. ELISA 
2. Rapid Latex Agglutination 
3. Rapid Tests 
4. Home Access 
5. Dot Immunobinding 
6. Urine 
7. Oral Fluid 
 
HIV-1 Viral Identification Assays 1. Plasma HIV RNA Assays 
2. Viral Culture 
3. DNA PCR 
4. p24 Antigen Assay 
 
HIV-1 Confirmatory Antibody Assays 1. Western Blot 
2. Indirect immunofluorescence 
3. Line Immunoassay 
4. Radio immunoprecipitation Assay 
 
HIV-2 Monitoring Tests 1. Lymphocyte Analysis 
2. Viral Identification Assays 
i. Reverse transcriptase Polymerase 
Chain Reaction (RT-PCR) 
ii. Branched DNA Assay (bDNA) 
iii. Nuclei Acid Sequence based 
assay (NASBA) 







One of the major limitations of serological POC diagnostic tools is specificity. There has been a 
consensus on the specificity of some of these tests. In cases of false positives, confirmatory testing is 
required, and when another serological test was used, there were flaws in the performance as 
highlighted by work done by [30]. According to a study performed in the Democratic Republic of 
Congo, the most probable causes of the false-positive results were serological cross-reactivity or non-
specific immune reactivity [31]. 
For HIV POC diagnostics that include non-blood fluid samples such as saliva and urine, they offer the 
same advantages as serological tests and have more patient approval because of their non-invasive 
nature. HIV POC diagnostics show comparable accuracy to serological tests [32] and therefore one 
could apply the same serological tests limitations to such tests. 
Another important HIV POC diagnostic tool is the use for CD4 counts. POC tools for CD4 counts 
include flow cytometric devices, cartridges with microfluidic adaptations to flow cytometry or 
immunochromatographic strips [6]. Some of the advantages of such CD4 count POCs are that they 
offer rapid results and absolute CD4 counts. Two major limitations of CD4 count POCs is that they 
are relatively expensive and offer limited throughput of results [33]. An improvement to newer CD4 
count POC diagnostic tools by incorporating biochips eliminates the manual sample preparation 
process step, which was one of the limitations of these devices [6]. 
With the current available POC tools, there is still a need for simple and cost effective POC 
diagnostics for EID for viral load determination. The current diagnostic tools for EID and viral load 
testing are expensive and some require laboratory infrastructures for support and those that are not are 
not readily available in resource limited settings [33]. It is believed that anti-retroviral therapy (ART) 
programs in resource limited settings that do not have access to simple and cost effective HIV POC 
diagnostics lead to treatment failure thereby impacting the quality of clinical management [33]. If the 
need for HIV viral load POC diagnostics is met, there is an expected reduction in the cost of ART 
programs and a reduction of laboratory infrastructures required [23]. 
The requirement for an automated, compact and portable, user-friendly, accurate, highly sensitive, 
contained POC diagnostic tool that requires minimal human involvement (decrease exposure of 
infectious agents to health personnel) with a high turnaround time, high throughput of sample 
processing and that is accessible by the poorest and most vulnerable people in resource limited 






2.2.2 TB POC Diagnostics and the Need for Portable, Automated, Cost 
Effective, High Volume and Rapid Sample Processing Diagnostic Systems. 
 
Tuberculosis is still one of the world’s deadliest communicable diseases. TB has an enormous global 
burden, with an estimated 9 million people worldwide developing TB in 2013 alone and TB diagnosis 
remains  a problem [13]. The epidemic is most deadly in high burden countries with high HIV 
prevalence. An estimated 1.1 million (13%) of the 9 million people who developed TB globally in 
2013 were HIV-positive and Africa was the region with most of the HIV-associated TB cases [13]. 
Conventional TB diagnosis mainly relies on sputum smear microscopy, culture, tuberculin skin test 
and chest radiography. These tests do provide the needed diagnosis and are often used in resource 
limited settings however they do have several limitations. Some of these diagnostic tests have shown 
to be insufficient to help the control of TB in HIV ravaged regions [34]. Figure 2.3 shows some of the 
available TB diagnostic platforms being used in the current health care system. Amongst the current 
available TB diagnostics, there are those that can be classified as POC and those that are immune 
based systems of which some involve serological tests. Focusing on some of these available 
diagnostics, we discuss their strengths and limitations. 
Sputum smear microscopy offers the following advantages to some extent such as; its relatively 
inexpensive, rapid (i.e. offers same day results when direct Ziehl-Neelsen microscopy is used in 
conjunction with LED fluorescence microscopy) and its non-requirement of specialized equipment 
such as the microscope which also can be used for other scientific purposes such as the diagnosis of 
other infectious diseases such as malaria and urinary tract infections. However, this diagnostic test has 
its limitations which includes the requirement of laboratory infrastructure and well-trained technician 
on-site [33]. These factors alone make this platform less viable for the much required high throughput 
and accurate POC TB diagnostics in resource limited settings where there are health personnel and 
laboratory infrastructure shortages. 
Culture based growth detection tests are one of the most traditional and common reliable tests in 
resource limited settings. Culture based tests have high sensitivity and allows identification of 
mycobacterium tuberculosis and the differentiation between drug-sensitive and drug-resistant strains 
[35]. This diagnostic test has many limitations such as the requirement of laboratory infrastructures 
(Biosafety level, BSL 2 or BLS 3) and trained personnel. It also has a turnaround time of 2-6 weeks 
which is not ideal for high disease burdened regions with stretched resources. Depending on the 
disease burden of the region and availability of laboratory structures, this test can be very expensive 
(consumables, safety equipment, transportation and storage of samples etc.), as large incubation 






Figure 2.3: A schematic diagram showing various available TB diagnostic platforms. Amongst 
the current available TB diagnostics, there are those that can be classified as POC and those 
that are immune based systems of which some involve serological tests. For example; sputum 
smear microscopy offers the following advantages to some extent such as; its relatively 
inexpensive, rapid (i.e. offers same day results when direct Ziehl-Neelsen microscopy is used in 
conjunction with LED fluorescence microscopy) and its non-requirement of specialized 
equipment such as the microscope which also can be used for other scientific purposes such as 
the diagnosis of other infectious diseases such as malaria and urinary tract infections. Culture 
based growth detection tests are one of the most traditional and common reliable tests in 
resource limited settings. Culture based tests have high sensitivity and allows identification of 
mycobacterium tuberculosis and the differentiation between drug-sensitive and drug-resistant 
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These limitations hamper the decentralisation of culture based tests in resource limited settings as 
governments are forced to build less laboratory infrastructures leading to overcrowding of already 
existing infrastructures ultimately leading to large volumes of unprocessed samples and increased 
turnaround times to get results to patients. 
Most TB diagnostics used at POC are the humoral immune response tests (e.g. serological tests for 
antibody detection); cellular immune response tests (e.g. Interferon-Gamma Release Assays (IGRAs), 
tuberculin skin tests etc.) and antigen detection tests (e.g. urine LAM tests). These POC tests offer a 
rapid (same day results), are inexpensive and require minimal training for performing the tests. In 
spite of the inexpensiveness of these tests, they are known to be highly inaccurate, inconsistent and 
often associated with poor sensitivity. Due to these limitations, for example, antibody detection tests 
are not WHO recommended for clinical use [33]. 
Nucleic acid amplification tests (NAATs) have been evaluated for TB diagnosis and detection of drug 
resistance for nearly two decades [47]. NAAT tests offer many advantages such as high specificity, 
high accuracy, minimal training required for health personnel, rapid results (get results within 90 
minutes). The most common NAAT is the Xpert MTB/RIF system which also provides MDR-TB 
screening. The Xpert MTB/RIF assay simultaneously detects mycobacterium tuberculosis (MTB) and 
rifampin (RIF) resistance by PCR amplification. The Xpert MTB/RIF offers accurate results and has 
the potential to be used for TB POC diagnostics as it requires minimally trained health personnel. 
However, the Xpert MTB/RIF fails to meet the important POC requirements on two important 
grounds: at current prices, it is expensive and unaffordable in many resource limited settings and it 
requires sophisticated equipment that cannot be deployed at the community level [33]. A further 
drawback of the Xpert MTB/RIF assay is that in developing countries, its pricing in the private sector 
is higher than that in the public sector further imposing barriers in its accessibility to patients. 
With the current TB diagnostic tools available, it is evident that the most effective tools are still 
laboratory based and one of the potential POC tests, the Xpert MTB/RIF has a major economical 
drawback that comes with it. Most TB diagnostics still require trained health personnel and a lot of 
human involvement in the sample preparations. 
With this in mind, one could say that a new TB POC diagnostic tool that is automated, compact and 
portable, user-friendly, accurate, highly sensitive, and requires minimal human involvement (decrease 
exposure of infectious agents to health personnel) with a high turnaround time and high throughput of 
sample processing is highly required. Most importantly, this POC must be accessible to the poorest 






2.3 Global Investment in HIV/AIDS and TB Management 
Programs and the Unmet Needs in HIV/AIDS and TB POC 
Diagnostics.  
 
Based on the current available POCs platforms for HIV and TB diagnosis, an effective way to have 
these epidemics under control is the design, development and implementation of economical viable 
solutions to HIV and TB diagnosis in resource limited settings. It is estimated that diagnostics 
comprise about 3-5% of the health care spending only, yet it has an impact of about 70% on health 
care decisions, therefore relatively modest investment in diagnostic technology could potentially lead 
to drastic improvements on the overall health care service delivery system [48]. 
An estimated global expenditure of about US$ 19.1 billion was available from all sources for the 
AIDS response in 2013 [11]. Global funding for TB prevention, diagnosis and treatment was 
estimated to be US$ 6.3 billion in 2014 [13] and this excludes resources required for research and 
development for new TB diagnostics, drugs and vaccines. An estimated US$ 2 billion a year is 
required for research and development for new TB diagnostics, drugs and vaccines. A major source of 
funding in the global fight against HIV and TB epidemics has been the US President’s Emergency 
Plan for AIDS Relief (PEPFAR) [49]. PEPFAR has contributed about US$ 46.5 billion through the 
United States government bilateral HIV/AIDS programs, about US$ 1.9 billion to United States 
government bilateral TB programs and about US$ 10.6 billion through the Global Fund, in total over 
US$ 59 billion has been provided by PEPFAR from 2003 to 2014 to support HIV/AIDS and TB 
programs [50]. Many new diagnostic technologies are under development and some are steadily 
entering the market, even with the enormous global expenditure mentioned above, funding is still 
required to rapidly evaluate whether these tests are accurate and ready for implementation. 
The unmet needs of HIV diagnosis in Sub-Saharan Africa and other resource limited settings are 
clearly substantiated by the lack of ‘suitable’ HIV POC diagnostic platforms for adult diagnosis, early 
infant diagnosis (EID) and for viral load measurements. The term ‘suitable’ here refers to simple, 
affordable, quick, accurate, equipment-free, automated, high sample processing throughput and user-
friendly. Unmet needs in TB diagnosis can be seen by the lack of an affordable ‘dipstick’ type of 
molecular TB POC test that offers POC tests for all forms of active TB, regardless of HIV status or 
CD4 count, which is laboratory decentralized, affordable and self-contained (to provide safety for 
health personnel). 
Despite the efforts and financial resources that have been invested, suitable HIV and TB POC 
diagnostics for resource limited settings are still unavailable. To reduce the global expenditure and 
required funding for HIV/AIDS and TB programs and simultaneously provide a support structure for 




HIV/AIDS and TB epidemics, an ideal POC diagnostic platform that encompasses some of the 
following specifications ideal for POC delivery [51] is required: 
 
i. Readout and Medical decision: User-friendly platforms that require at most one day of 
training time for health technicians operating the POC diagnostic tool this and should also 
provide conclusive results that allow a medical decision to be made, e.g. if treatment initiation 
is required depending on the results. 
ii. Sensitivity and Specificity: When performing tests, it should have high sensitivity for a wide 
range of infection types regardless of HIV status or CD4 counts, age (adult or infant) 
compared to other testing methods. 
iii. Time to results: Patients must receive results the same day. A desirable timeframe would be 
15 minutes to 3 hours depending on the test and number of tests required. 
iv. Throughput: Be able to do more than 20 tests per day by a single laboratory technician. 
v. Specimen type: Depending on age, for adults, desired specimens would be urine, oral swabs, 
breath, finger pricked blood, and if necessary sputum. For children/infants, desired specimens 
would be urine, oral swabs, finger/heel pricked blood. 
vi. Reagents: Small volume of reagents to help reduce test cost. 
vii. Instrumentation: A platform that is light, portable (increasing the access of health diagnostics 
by poorest and vulnerable people) with less maintenance cost and works in all POC field 
conditions (e.g. atmospheric conditions such as temperature and humidity conditions, and also 
environmental conditions such as high and low altitudes etc.). 
viii. Sample preparation: Automated to reduce human involvement. 
ix. Power Source:  Preferably easily rechargeable battery power platforms. 
x. Waste disposal: Environmental acceptable disposal, and normal sharps disposal protocols (if 
sharps where required for the test), desirably sharps should not be required to reduce 
infectious agents exposure to health care technicians [14]. 
xi. Cost: Desirably ZAR 100 or US$10 per test after scale-up. 
A scientific platform that offers commitment to the development of HIV and TB POC diagnostic 
devices in Microfluidic Large Scale Integration (MLSI). This leads to understanding the curiosity of 
what microfluidics really is and how it addresses the specifications of an ideal HIV and TB POC 







2.4 Microfluidics  
 
2.4.1 Historical Background of the Development of Microfluidic Systems. 
 
Microfluidics encompasses the science and technology of small volumes (10−9 to 10−18  litres) of 
fluid (liquids and gases) manipulation in channels having cross-sectional dimensions in the order of 
tens to hundreds of micrometre [2, 52]. The distant microfluidic origins lie in micro-analytical 
methods such as gas-phase chromatography, high pressure liquid chromatography and capillary 
electrophoresis and  it does not come as a surprise that the first miniaturized microfluidic device was a 
gas chromatographic analyser fabricated on a silicon (Si) wafer that was developed at Stanford 
University in the 1970s [53]. The first high-pressure liquid chromatography (HPLC) column 
microfluidic device fabricated using Si-Pyrex technology was developed and then published in 1990 
by Manz [54]. The combination of these micro-analytical methods that form the origins of 
microfluidics and the emergence of laser use in optical detection gave microfluidics the ability to use 
very small quantities of samples and reagents to perform separations and detections with high 
resolution and sensitivity [2].  
Besides molecular analysis, microfluidic technology advancements can be attributed to other fields 
such as biodefense, molecular biology and microelectronics. The advent of chemical and biological 
weapons on the global forefront, provide an opportunistic time for microfluidic technologies to be 
further developed since these weapons posed major military and terrorist threats. To counter these 
threats, the Defence Advanced Research Projects Agency (DARPA) of the US Department of 
Defence supported a series of programmes aimed at developing field-deployable microfluidic systems 
designed to serve as chemical and biological threat agent detectors [2]. One such developed 
microfluidic device was the Autonomous Pathogen Detection System (APDS) [55]. Increase in the 
demand for improved microanalysis methods in molecular biology due to advancements in genomics 
in the 1980s especially the need for high-throughput DNA sequencing further stimulated the 
advancement of microfluidic technology. 
The most contributing stimulant to advances in microfluidic devices was microelectronics. Processes 
such as photolithography and other techniques that had been successful in silicon microelectronics 
and in the microelectromechanical systems (MEMS) had a direct impact on microfluidics [2], 
especially on the fabrication  processes needed to form micro-channels.  
Since its birth, microfluidics has many platforms which vary in the way fluids are manipulated, 




application of the microfluidic technology. This milestone stimulated the further development of 
microfluidic technology for molecular biology especially in genomics.  
The ability to use very small quantities of samples and reagents, and when coupled with technological 
advancements; microfluidic devices can perform separations and detections with high resolution and 
sensitivity. For these reasons, the field of microfluidics is being used in molecular analysis, 
biodefense, molecular biology, microelectronics and medical diagnostics.   
2.4.2 Basic Principles of Microfluidics. 
 
There are three important parameters that help describe the basic principles of microfluidics, these are 
the Reynolds Number, Poiseuille’s Law and Surface Area to Volume Ratio. 
2.4.2.1 Reynolds Number. 
 
At the microscale level it is fluid viscosity that dominates fluid behaviour rather than inertia. For this 
reason, microfluidic flow is laminar and not turbulent, thus enabling the observation of cellular 
behaviour under high magnification. The flow of fluid through a microfluidic channel can be 
characterized by the Reynolds number. 
The Reynolds number is defined mathematically by equation (1) below, 
𝑅𝑒 =  
𝑙 ∙𝑉𝑎𝑣𝑔∙𝜌
𝜇
  …………………………………………………………………………...  (1) 
Where, l is the most relevant length scale and is given by 𝑙 = 4
𝐴
𝑃
 , A is the cross-sectional area of 
the channel, P is the wetted perimeter of the channel, µ is the viscosity, ρ is fluid density and 𝑉𝑎𝑣𝑔 is 
the average velocity of the flow. 
The Reynolds number 𝑅𝑒 depends on material properties like density and viscosity. For laminar flow, 
𝑅𝑒 ≪  1 and turbulent flow occurs at high Reynolds number, typically 𝑅𝑒 > 103 [56]. Due to the small 
dimensions of microchannels, the 𝑅𝑒 is usually less than 100, often less than 1 [57]. Reynolds 
numbers for common microfluidic devices can be estimated as follows. With water at 20 ºC and 1 
atmospheric pressure as the working fluid, typical fluid velocity is  𝑉𝑎𝑣𝑔 = 1 𝑐𝑚/𝑠, channel length 
scale as l = 100 µm, fluid density as ρ = 1.0 g/𝑐𝑚3 and fluid viscosity as µ = 10−3 Pa·s [56, 58, 59]. 
With these numbers, 𝑅𝑒 = [10−5 (𝑚) × 10−2 (𝑚/𝑠) × 103(𝑘𝑔/𝑚3)]/[10−3 (𝑘𝑔 𝑚−1𝑠−1)] = 0.1. 
This low value of 𝑅𝑒 affirms that microfluidic flow is laminar. Low values of 𝑅𝑒 in microfluidic 





2.4.2.2 Poiseuille’s Law. 
 
Since microfluidic flow is laminar, laminar flow of viscous and incompressible fluid, the pressure 
drop and the flow rate as well as the effective resistance might be obtained by using the Poiseuille 
Equation [57], shown by equation (2) below, 
∆𝑝 =  
8𝜇𝐿𝑄
𝜋𝑟4
  And     𝑅 =  
8𝜂∆𝑥
𝜋𝑟4
       …………………………………………….   (2) 
Where ∆𝑝 is the pressure drop, L is the length of the channel, r is the radius of the channel, R is the 
resistance to flow, 𝜂 is the dynamic fluid viscosity, Q is the volumetric flow rate and x is the distance 
in the direction of flow. 
 
2.4.2.3 Surface Area to Volume Ratio (SAV). 
 
One other characteristic principle of microscale and nanoscale devices is the Surface Area to Volume 
ratio (SAV). Typically, for large SAVs, surface forces (such as surface tension) are made the 
dominant force while the influence of inertial and body forces is greatly reduced [61]. Digital 
microfluidic technology utilises a microfluidic architecture that takes advantage of the effect of 
having large SAVs. In this technology, the droplets of water or oil are created and transported in a 
controlled fashion to achieve functions such as storage, mixing, chemical reaction or analysis in a 
discrete manner [61]. These droplets are formed using the surface tension properties of liquid and 
hydrophobicity control of the substrate is done using electrical fields and material coating [61]. 
Having large SAVs is a beneficial for on-chip microfluidic Capillary Electrophoresis (CE) devices as 
it increases efficiency in the microchannels by removing excess heat more rapidly [62]. Small SAVs 
in CE devices leads to the unfavourable effect of nonlinear flow, excessive heat dissipation and 
faradaic reactions [61]. However, when  transporting fluids using electrokinetic flow, the large  SAVs 
allows macromolecules to quickly diffuse and adsorb to channel surfaces thereby reducing the 
efficiency of the pumping [62]. Although there has been much research to diminish this problem, 









2.4.3 Microfluidic Platforms and Channel Fabrication Processes. 
 
2.4.3.1 Microfluidic Platforms. 
 
Microfluidics research was pioneered by individuals from the traditional engineering and science 
disciplines. Because of this, microfluidics research has evolved into a multidisciplinary field with 
widespread applications available on various microfluidic platforms. 
A microfluidic platform comprises of an easily combinable set of microfluidic unit operations that 
allows assay miniaturization within a consistent fabrication technology [26]. These platforms are 
mainly classified according to their fluid handling mechanisms. There are five major microfluidic 
platforms, and these are: 
I. Capillary 





I. Capillary Microfluidics 
This platform utilizes capillary forces as the driving force of liquids. Liquid movement is 
controlled by the wettability and feature size of the porous or micro-structured substrate [26]. 
Lateral flow tests commonly referred to as test strips (e.g. pregnancy test strip kit) are a good 
example of a capillary based microfluidic platform. The use of colour change within the visible 
light region of the electromagnetic wave spectrum is used as a detection criterion. 
II. Pressure Driven Microfluidics 
This is one of the most common and diverse microfluidic platforms that encompassed 
technologies used in other subcategories such as Microfluidic Large Scale Integration (MSLI), 
segmented flow microfluidics, linear actuated microfluidic devices and pressure driven laminar 
flow microfluidic devices. In this platform, pressure is used for fluid handling by: 
i. Mechanical displacement of the fluid itself, for example using a plunger system. 
ii. Creating pressure gradients which lead to hydro-dynamically stable laminar flow profiles 





iii. Pneumatic displacement of membranes using microvalves. 
N.B.: This project was performed in the Pressure Driven Microfluidics Platform, specifically Microfluidic 
Large Scale Integration (MLSI). A more detailed account of MLSI will be given in one of the following sections 
with “Microfluidic Large Scale Integration” as the title. 
III. Centrifugal Microfluidics 
In centrifugal microfluidics, all processes are controlled by the frequency protocol of a rotating 
microstructured substrate where the forces at play include the centrifugal force, Euler force, 
Coriolis force and the capillary force [26]. Assays are put into practise as a sequence of liquid 
operations arranged from radially inward positions to radially outward positions. Liquid transport 
is instigated by the centrifugal force directed outwards in the radial direction where the frequency 
of rotation makes it possible to scale the centrifugal force over a wide range of magnitudes [26]. 
Using a tunable flow resistance of the fluidic channels, small flow rates in the order on nL per 
second and high throughput continuous flows up to 1 mL per second can be generated [63]. This 
allows the successful scaling of flow rates over 6 orders of magnitude independent of chemical 
composition, ionic strength, conductivity and pH value of the liquid and because of this attribute, 
it opens a wide field of possible applications [26]. Depending on the channel geometry and 
wetting properties of the liquid, liquid transport at rest is realized by capillary forces. Liquid 
valves in centrifugal microfluidics are generally classified as passive valves [26]. These include 
valves like the geometric capillary valve [64], hydrophobic valve [65], centrifugo-pneumatic 
valve [66] and hydrophilic siphon valve [67]. Centrifugal microfluidics has the potential to be 















IV. Electrokinetic Microfluidics 
In electrokinetic microfluidics, the unit operations are controlled by electric fields acting on 
electric charges or electric field gradients acting on electric dipoles [26, 57]. Depending on 
buffers and the sample, several electrokinetic effects such as electroosmosis, electrophoresis, 
dielectrophoresis and polarization superimpose each other [26]. Of the above mentioned effects, 
electroosmosis can be used to transport the whole liquid bulk while the other mentioned effects 
can be used to separate different types of molecules or particles within the bulk liquid. In this 
platform, the microfluidic channel has a charged solid surface that induces an opposite net charge 
in the adjacent liquid layer [26]. When an electric potential is applied along the channel, the 
positively charged liquid molecules are attracted by electrostatic forces and thus move towards a 
corresponding electrode. Basically, fluid motion in electrokinetic microfluidics is superimposed 
by the movement of ions and charged molecules, which are either attracted or repelled by the 
electrodes depending on their charge and the velocity of these molecules depends on the charge 
and hydrodynamic radius [26]. The molecule’s charge and hydrodynamic radius provides a 
distinction between molecular entities and it is this distinction that is used in electrophoresis to 
separate charged molecules. 
V. Acoustic Microfluidics 
The microfluidic unit operations in this platform are mainly controlled by surface acoustic shock 
waves. The shock waves are generated by well-arranged surrounding sonotrodes which define the 














2.4.3.2 Microfluidic Channel Fabrication Processes. 
 
The manufacturing of microfluidic channels depends upon the material capabilities cost, intended 
microfluidic platform and ultimately the application area. Commonly used materials are corning 0211 
borosilicate glass fused silica, quartz silicon, polymethylmethacrylate (PMMA), polydimethylsiloxane 
(PDMS), SU-8, steel, aluminium and copper [70]. Table 2.2 below shows some of the different 
manufacturing/fabrication processes and the associated materials used. 
As an example, we described the fabrication processes performed in this project in the section titled 
“Microfluidic Large Scale Integration”. 
 
Table 2.2: Microfluidic Channel Fabrication Processes or Methods. The manufacturing of 
microfluidic channels depends upon the material capabilities cost, intended microfluidic 
platform and ultimately the application area. Information obtained from References [70-74]. 
Fabrication Process Materials Principle of the fabrication 
Process 
Lithography PDMS, PMMA, SU-8, Corning 
0211 borosilicate glass fused 
silica 
Using UV light and a series of 
chemical reactions to produce 
microfluidic channels and 
features. 
Microinjection Molding Amorphous Metallic Alloy 
(“metallic glass”), Cyclic Olefin 
Polymers and Cyclic Olefin 
Copolymers 
Transferal of micron or 
submicron features of metallic 
moulds to a polymeric product. 
Laser Ablation Copper, Steel Bond-Breakage by pulsed UV 
source 
Micromachining Steel, Copper, Aluminium Cutting of materials with tool 
Etching Silicon, Silicon dioxide, silicon 
nitride 
Chemically removal of layers 
(wet silicon etching) and/ or 
plasma assisted removal of the 






2.4.4 Fluid Control Systems. 
 
Various microfluidic devices have different channel networks depending on the fabrication process 
used like those mentioned earlier in the previous section. Typically, the cross-sectional shapes of the 
microchannels are either rectangular, square or circular. One of the most important components in 
microfluidic systems is the fluid manipulation methods. To perform fluid manipulation in fluidic 
systems, devices such as actuators, valves, pumps and mixers are used. However, in microfluidics, 
microvalves, micropumps and micromixers are used within the microfluidic devices. 
2.4.4.1 Microvalves 
 
The ability to manipulate fluid flow using valves is an essential principle of microfluidics. A compiled 
classification of the available microvalves in microfluidics is shown in Figure 2.4. 
Valves can either be active or passive. Active valves require energy whereas passive valves do not 
require energy for operation. The type of valve used in a device depends on the amount and type of 
control needed for the application. 
Most active valves often use external macroscale devices that control the actuation and provide the 
energy [62], these include electromagnetically actuated microvalves [75] and pneumatically driven 
pressure valves [3]. 
Passive valves can be used to limit flow in one direction, to remove air or to provide a temporary flow 
stop and the most common way of constructing passive valves involves the use of porous hydrophobic 
materials or surface treatments to create selective vents or flow stops [62]. In such a system which 
uses porous hydrophobic materials, vents control the fluid movement by allowing air to pass, but not 
the liquid being moved. 
 The work described in this project makes use of the following valves: 
i. External active microvalves that are actuated by the aid of external pneumatic means. This is 
highlighted in Figure 2.4, i.e. ‘in-line’ pneumatic microvalves. The full description of this 
microvalve will be given in the ‘Microfluidic Large Scale Integration’ section. 
 
ii. External active microvalves that are micro-electrically actuated. This is highlighted in Figure 
2.4, i.e. ‘rotary’ modular microvalves. A modular rotary microvalve valve, has origins of the 
multi-directional switching valve  with a rotary mechanism developed by Hasegawa [76]. 
This microvalve requires continuous power to be applied to keep the valve actuation in 





Figure 2.4: The different types of microvalves. Valves can either be active or passive. Active 
valves require energy whereas passive valves do not require energy for operation. The type of 
valve used in a device depends on the amount and type of control needed for the application. 
The work described in this project makes use of the highlighted valves. This classification of 




















































One of the first micropumps was developed by Smits in the late 1980s [80]. Since then, there has been 
advancements in the fabrication and development of micropumps and earlier classifications by 
Krutzch and Cooper [81] made it possible to identify a micropump suitable for each of the emerging 
microfluidic platforms. Figure 2.5, shows a compiled classification of the available micropumps in 
microfluidics.  
Depending on their construction, pumps are usually classified into two main categories: 
i. Displacement pumps  - which exert pressure forces on the working fluid through one or more 
moving boundaries [82], also referred to as mechanical pumps, because there is movement of 
parts. 
 
ii. Dynamic pumps – which continuously add energy to the working fluid in a manner that 
increases either its momentum or its pressure directly [82], also referred to as non-mechanical 
pumps, because of the absence of moving parts. 
Many displacement pumps operate in a periodic manner, incorporating some means of rectifying 
periodic fluid motion to produce net flow, and often such pumps are subcategorized into the 
reciprocating displacement pumps and peristaltic pumps in which the moving surface is a diaphragm 
[79]. 
Dynamic pumps include centrifugal pumps, electrohydrodynamic pumps, magnetohydrodynamic 
pumps, electroosmotic and acoustic-wave micropumps. Most dynamic pumps are ineffective at low 
Reynolds number (e.g. centrifugal pump) and thus have been miniaturized to a limited extent [82].  
Due to the limited extent of miniaturization of dynamic micropumps as mentioned above, the 
micropump of choice in this project was the pneumatic micropump classified as a reciprocating 
diaphragm pump, and it is highlighted as such in the Figure 2.5. More details of the functionality of 






Figure 2.5: The different types of pumps and micropumps. Depending on their construction, 
pumps are usually classified into two main categories, displacement and dynamic. Displacement 
pumps exert pressure forces on the working fluid through one or more moving boundaries and 
dynamic pumps continuously add energy to the working fluid in a manner that increases either 
its momentum or its pressure directly. The micropump of choice in this project is highlighted 


































































Besides the microvalve and the micropump, the micromixers are often the important and 
indispensable components in microfluidic platforms as the mixing of fluids is a basic process required 
for biological applications. At microscale level where laminar flow is prevalent, mixing occurs by 
diffusion. However, for some microfluidic-based assays, particularly those that require relatively large 
particles (i.e. cells) to mix, the diffusion process is slow [62]. There are two ways of mixing in 
microfluidics, using active micromixers and passive micromixers. A list of micromixers and their 
respective classification is given in Figure 2.6. 
Passive micromixers use channel geometry to fold fluid streams to increase the area over which 
diffusion occurs [62]. Y/T-type flow, recirculation flow and Droplet micromixers are all examples of 
passive micromixers. 
Active micromixers are those that use external sources to increase the interfacial area between fluid 
streams [62]. Electrokinetically-driven, acoustically-driven and magnetodynamic-driven micromixers 
are examples of active micromixers. Another crucial active micromixer is a combination micromixer 
which has integrated microvalves and micropumps. 
The type of mixer preferred generally depends on the type of reagents that need mixing and the fluid 
regime operation (i.e. Re number) [62]. In this project, the preferred choice of micromixer that is 
consistent with the microfluidic platform used is the active micromixer which has integrated 
microvalves and micropumps. The details of how this pump functions will be explained in the 
















Figure 2.6: The different types of micromixers. There are two ways of mixing in microfluidics, 
using active micromixers and passive micromixers. Passive micromixers use channel geometry 
to fold fluid streams to increase the area over which diffusion occurs. Active micromixers are 
those that use external sources to increase the interfacial area between fluid streams. The type 
of mixer preferred generally depends on the type of reagents that need mixing and the fluid 
regime operation (i.e. Re number). In this project, the preferred choice of micromixer that is 
consistent with the microfluidic platform used is the active micromixer which has integrated 
microvalves and micropumps, this is highlighted above. This classification of micromixers was 

























Microfluidic Large Scale Integration (MLSI) is a microfluidic platform that refers to a microfluidic 
channel circuitry with chip-integrated microvalves based on flexible membranes between a liquid-
guiding layer and a pneumatic control channel layer [26]. 
Microfluidic large scale integration platform emerged in the 1990s as evidenced in the early work 
published by Abbott, Singhvi and Kumar and many others in the Whitesides research group [83-85]. 
A few years later, after success in the lithographic molding of structures with sub‐micrometer 
dimensions [86], a novel fabrication technology for microfluidic channel development called soft 
lithography arrived on the global scene [87]. This technology is mainly based on the use of 
elastomeric stamps, master molds, conformable photomasks which are then later used to fabricate and 
replicate microstructures. This technology was a major success using the rubber like elastomer, 
polydimethylsiloxane (PDMS) which had the needed optical transparency, biocompatibility (with 
aqueous solutions), gas permeability, inertness and non-toxicity to perform biochemical/biological 
experimentation and microscopic observations.  
The technology was improved and expanded by Stephen Quake’s research group who reported a 
series of microfluidic systems which used a multilayer soft-lithography (MSL) process [3]. This 
allowed several layers of PDMS to be bonded on top of each other to produce a monolithic, multi-
layered PDMS structure. This was the birth of a new type of microvalve in microfluidics and is now 
commonly being referred to as the Quake valve. The Quake valve is classified as a pneumatically 
actuated in-line microvalve and it is now the core microvalve and fabrication process in the MLSI 
platform based microfluidic systems. 
The two functional states of the microvalve, the open and closed state, are dependent upon the applied 
pneumatic pressure on the control channel layer. The development of a microfluidic chip that has 
thousands of microvalves and the manner in which microvalves are configured and laid out leads to 
the formation of fluidic control units such as micropumps, micromixers, multiplexers etc. all in a 
single microfluidic chip. This Quake developed technology and its novel microvalve functionality is 
being made commercially available to the scientific community by the company, Fluidigm Corp., CA, 






2.5.2 Device Fabrication. 
 
Microfabrication has its foundations in microelectronics. Microfabrication is a process used to 
construct physical objects with dimensions in the micrometer to millimeter range using some of the 
already established fabrication processes used to make integrated circuits [88]. 
Microelectromechanical systems (MEMS), lab-on-a-chip (LOC) and micro-total analysis systems (µ-
TAS) are all microfabricated devices and have been a success in the commercial and scientific 
research industries. Microfabrication offers more uniform, accurate and reproducible flow chamber 
geometries that can be precisely constructed as compared to conventional machining (e.g. injection 
moulding). Most microfluidic devices are fabricated using photolithography, soft-lithography and 
popular multi-layer soft-lithography. We now present the principle of these fabrication processes. 
 
2.5.2.1 Photolithography and Soft-Lithography. 
 
Photolithography is the microfabrication process of transferring geometric patterns envisioned by a 
designer onto a physical surface of compatible material, usually a silicon wafer. Photolithography is 
the most successful microfabrication technology since its invention in 1959 and since most of the 
integrated circuits are made using this technology, it has been applauded as the workhorse of the 
semiconductor industry [87]. 
The photolithographic technique currently used for manufacturing microelectromechanical structures 
is based on a projection printing step in which the image of the geometric pattern is reduced and 
projected onto a thin film of photoresist that has been spun-coated onto the surface of a either a 
silicon, glass or plastic wafer through a high numerical aperture lens system [87, 88]. For microfluidic 
devices, an improved method was developed, which allowed the replication of the pattern and this is 
called soft-lithography. 
 
Soft-lithography has the same pattern transferal principles as photolithography, however, in this 
process; the pattern replicating is done using elastomeric polymers. Therefore, soft-lithography is 
referred to as a non-photolithographic method for replicating a pattern [52]. The microfabrication 
process of soft-lithography follows a sequence of process steps (a process flow) that can be 
categorized into three major collective processes, namely, concept developing, rapid prototyping 













Figure 2.7: Schematic of microfluidic device fabrication using soft-lithography. Soft-lithography 
has the same pattern transferal principles as photolithography, however, in this process; the 
pattern replicating is done using elastomeric polymers. The microfabrication process of soft-
lithography follows a sequence of process steps (a process flow) that can be categorized into 
three major collective processes, namely, concept developing, rapid prototyping and replica 
molding. In concept developing, device designing in done using a computer-aided design (CAD) 
program to make a photomask. In rapid prototyping, the photomask is then used to perform 
photolithography. The replica molding process involves the casting of a transparent, silicone-





















In concept developing, the first step will be the device designing. Device designing is usually done in 
a computer-aided design (CAD) program (e.g.  AutoCAD® software). In this step, the designer needs 
to consider the size of the channels, shape of the channel (i.e. straight or curved) and also the nature of 
the angled features within the minimal feature sizes attainable in respect to photolithography. High 
resolution printing would be the next step, in which a high resolution commercial image setter is used 
to print the pattern on a transparency film. High resolution printing allows one to obtain design 
features with sizes up to about 8 microns (8µm) [89]. The printed transparency will serve as the 
photomask for the next step in the process. The photomask can be printed as clear-field (for positive 
photoresist) or dark-field (for negative photoresist) dependant on the photoresist to be used. 
 
In rapid prototyping, the photomask is then used to perform photolithography. Positive or negative 
photoresist is spin coated on a clean silicon wafer at specified thicknesses as required for each 
designed features and then exposed to UV light. UV light passes only through the clear regions in the 
mask onto the photoresist spun silicon wafer to selectively crosslink the features represented by 
photomask. Once the photoresist is exposed, it is developed with photoresist-specific solvents that 
remove un-cross-linked polymers. The final result after developing is the ‘master mold’, whose 
features precisely represent the desired device structures. Figure 2.8, shows the rapid prototyping step 
in soft-lithography when using either positive or negative photoresists and the resultant master mold 
features that are obtained after developing while Figure 2.9 (a) shows a diagrammatic illustration of 
obtaining the master mold. 
The replica molding process involves the casting of a transparent, silicone-based liquid pre-polymer, 
against the master mold using an elastomeric material (e.g. PDMS) to generate a negative monolayer 
(or monolithic layer) replica of the master [57]. The pre-polymer is poured onto the master wafer and 
heat-cured in place to form a rubbery silicone solid. The replica molding process using an elastomeric 
material is the backbone of soft-lithography and the process is illustrated using Figure 2.9 (b). The 
silicone that has heat-cured on the master mold is then peeled off to reveal the inverted pattern 
topology represented on the mold. Access ports, i.e. the inlet and outlet ports are punctured using a 
cylindrical punch. It is then attached to a coverslip surface and heat-cured again. After this step the 





























Figure 2.8: The photolithography and soft-lithography process. Positive or negative photoresist 
is spin coated on a clean silicon wafer at specified thicknesses as required for each designed 
features and then exposed to UV light. UV light passes only through the clear regions in the 
mask onto the photoresist spun silicon wafer to selectively crosslink the features represented by 
photomask. Once the photoresist is exposed, it is developed with photoresist-specific solvents 






























































































































whose features precisely represent the desired device structures. The steps in this process were 




Figure 2.9: (a) The master mold fabrication and (b) the replica molding processes in soft-










2.5.2.2 Multilayer Soft-Lithography. 
 
Multilayer Soft-Lithography (MSL) developed by the Quake research group is an extension of the 
soft-lithography technique developed by the Whitesides research group. MSL provides the capability 
to bond multiple monolithic layers of elastomeric material created during the replica molding 
processes [3]. The process is similar to the soft-lithography process. 
In the concept developing step, after the entire design/pattern architecture of the microfluidic device 
has been completed, the design is separated into multiple layers where all features of a given height 
are placed on a single layer and then printed in high resolution to produce a photomask. The 
photomasks are printed according to the channel architecture where some layers will be printed on a 
positive (clear-field) photomask and some on a negative (dark-field) photomask.  
Rapid prototyping is then performed using the photomasks. Both negative and positive photoresists 
are used and often the positive photoresist is used to produce rounded channels. Square channels 
become rounded because a reflow occurs when the positive photoresist spun silicon wafer is baked at 
high temperatures [3]. Similar developing techniques and reagents are used, and each layer will have 
its respective master mold. 
The extension of this technique to the already existing replica molding process is that, each layer of 
elastomeric material is cast separately and then later bonded together [3]. In this case, the elastomeric 
material that is used is PDMS, thus this process can be referred to as a PDMS replica molding process 
[93]. After the bonding process, the resultant microfluidic device is a monolithic three-dimensionally 
patterned structure composed entirely of elastomeric material [3]. MSL makes it possible to create 
multiple layered fluidic devices. A unique concept that was brought about by MSL was the 
establishment of an active, external, pneumatically actuated in-line microvalve and a pneumatically 
driven series multi-chamber reciprocating displacement micropump. Depending on the arrangement 
and geometry of the microvalves, there are two forms of the micropump, a linear pneumatic peristaltic 
and rotary pneumatic peristaltic micropump [3]. The device can also have a unique micromixer, 
which is the integration of the active, external, pneumatically actuated in-line microvalve and the 








2.5.3 General Principle: Microvalve, Micropump and Micromixer. 
 
The basic principle behind functionality of the Quake valve is that the pneumatic channel can be 
deformed under pressure to pinch off the flow of fluids in an in-line microchannel. Two monolayers 
(e.g. control channel and flow channel) casted separately via the PDMS replica molding process are 
bonded together, on top of each other with the control channel and flow channel intersecting 
orthogonally [3, 94]. The resultant bonded PDMS structure is then sealed on top of a glass substrate as 
shown in Figure 2.10. 
A microfluidic device can be configured in two architectural designs: ‘push-down’, in which the flow 
channels are located below the control channels as shown in Figure 2.10 (a), and ‘push-up’ in which 
the flow channels are bonded on top of the control channels as shown in Figure 2.10 (b), or an 
architectural design with both push-up and push down valves as shown in Figure 2.10 (c), [1]. 
When pressure is applied to the control channel during actuation, the flexible membrane at the 
intersection of the channels is deflected, thereby closing the channel. This is illustrated by Figure 
2.11. Typical channel sizes are 100 microns wide and 10 microns high, making the active area of the 
valve 100 microns by 100 microns and the membrane is usually made to be 30 microns thick [3]. The 
nature of the membrane, i.e. the width, height and thickness determines the valve actuation pressure 
level [1]. Push-down designed devices allow channels to be in direct contact with a substrate, assisting 
applications which require custom-functionalized surfaces [95]. Push-down designed devices 
generally require high pressures to actuate since the control layer is the thicker layer and also because 
of this, push down designed devices have limited heights for the flow channel [1]. Push-up designed 
devices allow the use of taller flow channels, and since the control channel is the thinner channel, it 
requires low pressures for actuation. 
There should be a rounded profile in the flow channel and a rectangular profile in the control channel 
if the valve has to close completely during actuation or else the rectangular flow channel and 
rectangular control channel will produce a ‘sieve’ valve, and these are also illustrated in Figure 2.11 
[3]. Sieve valves can be used in applications where the manipulation of an assortment of different 
sized cells, beads, droplets and other large objects is required, because the valve opening can be 











Figure 2.10: A microfluidic device can be configured in two architectural designs: ‘push-down’, 
in which the flow channels are located below the control channels as shown in (a), and ‘push-up’ 
in which the flow channels are bonded on top of the control channels as shown in (b), or an 
architectural design with both push-up and push down valves as shown in (c). The image was 













Figure 2.11: Side view illustrating the functionality of the two-layer PDMS push-down and two-
layer PDMS push-up valves. When pressure is applied to the control channel during actuation, 
the flexible membrane at the intersection of the channels is deflected, thereby closing the 
channel. Push-down designed devices generally require high pressures to actuate since the 
control layer is the thicker layer and also because of this, push down designed devices have 
limited heights for the flow channel. Push-up designed devices allow the use of taller flow 
channels, and since the control channel is the thinner channel, it requires low pressures for 
actuation. There should be a rounded profile in the flow channel and a rectangular profile in 
the control channel if the valve has to close completely during actuation or else the rectangular 
flow channel and rectangular control channel will produce a ‘sieve’ valve. Sieve valves can be 
used in applications where the manipulation of an assortment of different sized cells, beads, 
droplets and other large objects is required, because the valve opening can be precisely 











When 3 of these microvalves are linearly arranged, with specific spacing, on top or below a flow 
channel, a linear pneumatic peristaltic micropump is created and when the design architecture has 
rotary geometry in the flow channel and 3 microvalves arranged on top or below the flow channel, a  
pneumatic peristaltic rotary micropump is created as shown in Figure 2.12 and Figure 2.13 
respectively [3]. A peristaltic pumping function occurs when the 3 microvalves are actuated in the 
pattern 101,  100,  110,  010,  011,  001, where 0 and 1 represent valve open and valve closed states 
respectively [3]. An open valve is when there is no pressure applied in the control channel and valve 
closed state is when there is applied pressure in the control line thereby deflecting the membrane. 
There is no need for precision regulating external pressure sources for pumping because on-chip 
peristaltic pumping provides the required level of fluid flow [1]. 
The fluidic manipulation required in most biological experimentations is efficient fluid mixing. The 
versatility of MLS is that the pneumatic peristaltic rotary micropump can be used as an on-chip 
continuous-flow micromixer. Continuous-flow mixing is the dynamic mixing which takes place when 
two solutions are flowing down the channel continuously [79]. For the micromixer, two fluids rotate 
in the same flow channel loop/ring, and when the peristaltic pump is activated, the centre of each fluid 
flows faster than the edge. Therefore, the interface between the solutions keeps stretching and 
eventually there is a shorter diffusion distance allowed for mixing and drastically reduce the mixing 
times when compared to normal passive diffusion [1]. This micromixer is classified as an active 
micromixer which is an integration of microvalves and micropumps [79]. This micromixer can also be 
used for on-chip fixed-volume mixing, which is mixing of two different solutions (e.g. sample and 
reagent) of fixed volumes completely before the next stage of the process is performed [79]. 
In summation the Quake valve provides a precise control over fluid flow within microfluidic devices 
and is versatile in that it can be combined to form a variety of complex structures such as 









Figure 2.12: Linear pneumatic peristaltic micropump. When 3 of these microvalves are linearly 
arranged, with specific spacing, on top or below a flow channel, a linear pneumatic peristaltic 
micropump is created. A peristaltic pumping function occurs when the 3 microvalves are 
actuated in the pattern 101,  100,  110,  010,  011,  001, where 0 and 1 represent valve open and 












Figure 2.13: When the design architecture has rotary geometry in the flow channel and 3 
microvalves arranged on top or below the flow channel, a rotary pneumatic peristaltic 
micropump is created. A Rotary pneumatic peristaltic micropump is also used as the 







2.6 Point-Of-Care (POC) Testing Using Microfluidic Large Scale 
Integration 
 
2.6.1 Barriers to adoption POC technologies in Resource Limited 
Countries.  
 
In the global health community, there is an increasing demand for new ways to simplify and improve 
the efficiency and cost of diagnostics in the fight against infectious diseases. The new ways are 
expected to significantly increase the access level to robust, high-quality diagnostics especially in 
resource limited settings where the early detection and treatment of infectious pathogens is of 
paramount importance. 
The goal in sub-Saharan Africa is to test and treat at large scale for multiple patients at point-of-care, 
facilitates the decentralization of laboratory based diagnostic services. In the townships and villages 
of resource limited settings of sub-Saharan Africa, power running water and refrigeration are often 
intermittent or absent, therefore whatever assays that are to be performed have to be self-contained 
[19]. It is not the technology that defines a POC test, but it is the intent to use technology that defines 
a diagnostic process as POC testing [96].  In research and development of diagnostic tools, it is 
necessary to develop POC diagnostic technology that suits the available POC settings. In general, 
POC testing can be thought of as a spectrum of technologies  ranging from simplest to sophisticated, 
that can be operated by users who range from laypersons to highly trained persons, and the present 
POC technologies can be sub-categorized into target product profiles (TPP) in association with the 
POC testing setting as follows:  homes (TPP1), communities (TPP2), clinics (TPP3), peripheral 
laboratories (TPP4) and hospitals (TPP5) [96]. Figure 2.14, shows the present spectrum of POC 
testing according to [96]. 
For each TPP, there is a desired purpose. For home based POC testing, TPP1, the test can be 
performed by the untrained person, i.e. any lay person by following the instructions on the over the 
counter POC diagnostic technology packaging. The purpose of TTP1 testing is for self-assessment 
and if need be, referral to other TTP’s such as TPP2, TPP3 and TPP4. At community settings, TPP2, 
POC testing can be performed minimally trained health workers and the aim would be for referral to 
TPP3 and TPP4. Clinics, TPP3, which is one of the most common POC testing setting in resource 
limited settings offers rapid diagnostic testing (RDT) performed by trained health care providers. At 
TPP3, there is diagnosis and treatment offered as well as voluntary counselling. TPP3 is infrastructure 
based, thus does not provide a high level of access to the offered services especially in remote places 
of the resource limited countries. Because there is diagnosis and treatment at TPP3, there is no need 




treatment and monitoring of patients and all this is managed by trained health care personnel or 
laboratory technicians. These services are infrastructure based, and do not provide the decentralization 
of the much needed high quality diagnostic testing. Though TPP4 and TPP5 offer POC testing 
capabilities, these POC testing settings are impractical in resource limited countries where the ‘test 
and treat’ goal is required to be mobile and reach out to the people rather than the people coming to 
the test site. 
The widespread adoption of POC technologies has its challenges. Examples of these challenges that 
affect the adoption process is also highlighted by Pai [96], and these include: 
i. Awareness:  A lack of awareness by the health care service providers of the potentially 
available POC technologies that can be used instead of resorting to referrals to laboratories. 
ii. Training:  Untrained and informal health care service providers who lack the knowledge and 
training needed to implement and perform POC testing such that the error prone results 
decreases the health system’s faith in POC technology. 
iii. Support infrastructure: Most clinics and primary care centres lack support infrastructures such 
as, constant power supply, refrigerators, storage space, and waste disposal units. 
iv. Infection risk:  The health workforce, who primarily perform POC testing are unwilling to do 
tests that may expose them to the risk of infections. 
v. Economic: POC testing using certain POC technologies may be too expensive and 
unaffordable in many resource limited countries.  
vi. Singularity POC technology: Some available POC tests are often applicable for single 
diseases and there is worry that most infections are missed this way. There is need for a more 
diversified POC technology that reduces the chances of missing infections when one test is 
performed. 
vii. Cultural/societal:  Perceived lack of confidentiality and stigma may reduce acceptance of 
POC testing in the communities.  
 
There is need for therapeutic systems and POC technologies for clinical diagnostics to change the 
diagnostic platforms in resource limited countries and overcome the challenges responsible for the 
lack of widespread adoption of these systems and technologies. One such POC technology that 







Figure 2.14: In general, POC testing can be thought of as a spectrum of technologies  ranging 
from simplest to sophisticated, that can be operated by users who range from laypersons to 
highly trained persons, and the present POC technologies can be sub-categorized into target 
product profiles (TPP) in association with the POC testing setting as follows:  homes (TPP1), 
communities (TPP2), clinics (TPP3), peripheral laboratories (TPP4) and hospitals (TPP5). The 




2.6.2 The Promise of Using Microfluidic Large Scale Integration systems 
in POC clinical diagnostic Testing. 
 
For some infectious agents, tests are needed to better distinguish past from current infections while for 
some, improved POC methods are needed to return same-day test results so that patients can receive 
appropriate therapy while they are still at the clinic [19]. Unfortunately, a common aspect in resource 
limited settings is that they often lack modern laboratories, fully automated instruments that provide 
highly reproducible, quantitative and hence sensitive and accurate diagnostic results [17]. There are 
three approaches to diagnostic technologies as mentioned by Yager et al. [19] and these are: 
1. Permanent integrated instruments: These are mainly comprised of instruments found in 
centralized laboratories in developed countries. These systems are infrastructure dependent 
and are best suited for high throughput work. 
2. Pure disposables:  These mainly comprise of immunochromatographic-lateral flow devices. 
They provide POC diagnosis in areas without access to well-staffed, well-trained personnel 
and well-equipped clinical laboratories. Basically, this technological approach is for regions 
that do not offer permanent integrated instruments. Pure disposables rely on relatively 
inexpensive, off-the-shelf components and reagents making them relatively affordable.  
3. Disposables with a reader: This technological approach is a compromise that allows high 
performance with low per-test cost, but with added complexity (such as using a reader) while 
at the same time using single-use only disposables. Calibrants would be stored on the 
disposable and during the diagnostic test, the sample and waste would be retained within the 
disposables such that the reader does not need to be cleaned between sample loadings. 
 
Microfluidic large scale integration platform based systems can be thought of as a technological 
approach best suited in the ‘disposables with a reader’. The microfluidic large scale integration 
platform based systems have the potential to become the most adaptable platform in clinical 
diagnostics especially for high-throughput POC testing. Its fabrication process, which involves 
PDMS, is comparably cheap and strong for biological experiments, thus also enabling MLSI systems 
to have disposable units. MSLI thus provides low-cost device fabrication and cost-efficient POC 
diagnostic testing. MSLI platform based systems also offer biological automation found in a 
‘permanent integrated instruments’ technological approach such that the diagnostic testing minimizes 





























Figure 2.15: Hypothetical sketch showing a MLSI based system performing an ELISA. (a) A 
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Figure 2.15 shows a hypothetical sketch of how an MLSI based system could perform a capture and 
quantification test such as an enzyme-linked immunosorbent assay (ELISA). Figure 2.15 (a) shows a 
general experimental set-up at POC to perform an ELISA test. Figure 2.15 (b) shows a generic 
principle of an ELISA test and how it would be performed using an MLSI system. Patient samples, 
detection antibodies, and the wash buffer will be introduced into the microfluidic chip via an 
automated system with minimal human involvement. Direction and order of flow of the patient 
samples and reagents to the main flow channel in the detection area will be actuated by the on-chip 
microvalve action. The main flow line in the detection area will have capture antibodies already 
primed onto the surface of the channel beforehand. The patient sample (e.g. whole blood) will be 
flowed into the main flow channel. Assuming that these capture antibodies only bind to a specific 
antigen, if the sample is antigen containing (e.g. HIV +) the antigen (e.g. HIV virus) will bind to the 
capture antibodies and if it is antigen non-containing, nothing will bind to the capture antibodies. A 
wash buffer will then be flowed into the main flow channel to wash away all the antigens that are not 
bonded to the capture antibodies. Detection antibodies (e.g. with fluorescence markers) are then 
flowed into the main flow channel and these will bind to the antibody-antigen complex. During this 
step, if the sample is antigen non-containing, again, these will bind to nothing and will be washed 
away when the wash buffer is reflowed into the main flow channel. After the wash buffer washes 
away the ‘loose’ detection antibodies, i.e. those not binding to anything, the automated system will 
trigger the fluorescence detector to commence the detection procedure. Speculating, from patient 
sample introduction, such a system is expected have a time to results of 10-15 minutes. The results 
will then be available via a printout interpretable by a technician or clinician.  MLSI promises to 
perform such a diagnostic test at a large scale where thousands of samples are tested on a single chip 
simultaneously. This would make MLSI systems fast and high throughput diagnostic devices most 
suitable for resource limited settings. 
An example of a microfluidic device though not an MLSI based system, that was used for POC 
testing is the mobile microfluidic chip, referred to as the ‘mChip’, developed by the Sia group [97], 
specifically designed for diagnosis in resource limited settings. The mChip, which demonstrated how 
new manufacturing, fluid handling and signal detection procedure can be leveraged to overcome the 
challenges faced in real world applications [48], was successfully tested in Rwanda on hundreds of 
locally collected human samples [97]. The mChip, was introduced as an easy to use POC assay that 
replicated all steps of an ELISA at low material cost (about US $0.10) [97]. The mChip provided an 
antenatal-care diagnostic test of HIV and syphilis. The device simultaneously detected antibodies 
against HIV and Treponema pallidum (the causative agent of syphilis) from a needle-prick sample 
volume of blood [97]. The test sensitivities, for detection of HIV-specific antibodies and treponemal-
specific antibodies, respectively, were 100% (with 95% confidence interval of 98.6 - 100.0) and 95% 




C.D. Chin et al., the assays had a turnaround time of about 15 minutes and the sensitivities and 
specificities were comparable to commercial ELISA kits [97]. 
The mChip showed that it was possible for microfluidic technology to be used as a miniaturized 
ELISA in resource limited settings to perform what are usually lab-based immunoassays. Microfluidic 
materials are selected such that they minimize surface adsorption of analytes while at the same time 
allowing the analytes to move to the detection zones in the disposables [19]. MLSI systems offer such 
characteristics, the PDMS allows certain analytes to move to detection zones (except those that have 
small and hydrophobic molecules) and is excellent for fabricating low-fluorescence devices.  
However, MSLI based systems like most ground-breaking technologies, suffers some drawbacks in its 
widespread use. MLSI based systems might have a large initial start-up expense but because they 
have disposable components in the test e.g. the microfluidic chip, the overall cost per-test is expected 
to be relatively cost friendly when compared to commercially available laboratory tests. MSLI based 
systems need to be made more accessible to research in order to have the technology being used in an 
even wider range of biological and biochemical applications [1]. MSLI systems still need more 
redefined designs that involve high-level design architecture with many fluidic control modules and 
also to give it the much needed portability (i.e. a hand held or portable device with disposable 
cartridges) if it is to succeed in the POC testing environment. Examples of commercially available 
MLSI systems that can be categorized as ‘disposables with a reader’ are Fluidigm systems, such as the 
BioMark™ technology for molecular biology, the TOPAZ™ system  for protein crystallography and 
the Fluidigm®  EP1 system for genetic analysis developed by Fluidigm Corp.(CA, USA. However the 
Fluidigm systems are yet to be refined to be useable for POC testing. To just mention a few, the POC 
tests that would be most amenable to refined MLSI systems would be tests like the ELISA based tests 
for quantifying agents (e.g. HIV antibodies), complete blood count, Polymerase Chain Reaction 
(PCR) based drug susceptibility testing, MTB drug susceptibility testing [98].  
In summation, MLSI platform based microdevices, have the potential for creative designs that allows 
the development of a POC diagnostic toolbox containing a POC device or that has POC devices 
which perform a spectrum of clinical diagnostic testing ranging from HIV testing and monitoring 
(including CD4 cell count, viral loading measurement, DNA PCR etc.) to TB diagnosis and other 
opportunistic infections. The success of such a creation that is capable of simultaneously testing for 








CHAPTER 3: RESEARCH AIMS AND 
OBJECTIVES 
 
3.1 Problem Identification 
 
Microfluidic Large Scale Integration technology is expected to revolutionize laboratory procedures 
involving clinical diagnostics. Advances in the technology has offered exciting possibilities but many 
of the possibilities suffer from a variety of technological drawbacks that limit its widespread practical 
application in hospitals and patient settings especially the immediate point-of-care diagnosis of 
disease. For example, Fluidigm systems, such as the BioMark™ technology for molecular biology, 
the TOPAZ™ system  for protein crystallography and the Fluidigm®  EP1 system for genetic analysis 
developed by Fluidigm Corp.(CA, USA) are attempts of ‘plug and play’ automated chip control. 
However, they do not give the user dynamic control over the valves. These systems are limited to the 
commercial applications they present with no custom manoeuvrability i.e. they do not allow user to 
design their own microfluidic chip, for example, the Fluidigm PCR microfluidic chip has a hard-wired 
control system with no user dynamic manipulation. We believe that the system we aim to develop will 
allow dynamic real-time chip based manipulation of automation designs. 
The current microfluidic systems utilize a manual set-up process for off-chip to on-chip fluid 
transport. The off-chip to on-chip fluid transport is an essential process because it involves the 
functionalization of microfluidic chip control channels. The functionalization of the microfluidic chip 
control channels occurs when the control channels are filled with fluid and connected to a pressure 
source. The pressure source is actuated such that pressure is applied to the fluid in the control 
channels to close microvalves and no pressure is applied to the fluid in the control channels to open 
microvalves. 
For this reason, most microfluidic large scale integration systems are laboratory infrastructure 
dependent, where expensive support equipment and the meticulous attention of highly trained 
personnel are required. These systems becomes incompatible for field work deployment to point-of-
care testing sites in resource limited settings and very impractical to work with if the operation of the 
device requires the user to be thoroughly pre-trained in advance. It becomes even more impractical to 
use the current microfluidic systems on microfluidic chips with complex multi-layer architecture and 
have a high number of valves and fluidic inputs. Therefore, there is need to develop a microfluidic 
system that brings the practicality back such that these microfluidic systems can be used for point-of-





3.2 Research Aims and Objectives 
 
This research project partly relies on two clean room only processes, photolithography and soft- 
lithography. This research will utilize this special laboratory to perform a multi-layered soft-
lithographic micro-fabrication process. Tiny hair-sized water channels and chambers typically 100 
micro-meters (µm) wide and 10 µm high will be sculpted onto a prepared silicon wafer (i.e. 
photoresist spun coated) via a UV Mask Aligner. These channels are then to be cast onto a transparent 
cubic inch multi-layered polydimethylsiloxane (PDMS) chip and placed onto a glass substrate. The 
designed and fabricated microfluidic chips should have the capacity to perform complex 
multifunctional laboratory functions under the automated control of a multi-tasking computer with 
minimal human involvement for as many as one thousand patients on a single microfluidic chip the 
size of a postage stamp. 
 
Basically, this research project aims to design and develop a user friendly off-chip to on-chip fluid 
transport system that will interface micromechanical valves used in MSLI and macro-mechanical 
valves used in High Pressure Liquid Chromatography (HPLC) such that a microfluidic system can be 
operated by one individual. The goal is to project MLSI towards achieving low cost, portable point-
of-care medical diagnostic solutions for the growing crisis caused by HIV/AIDS and TB epidemics. 
3.3 Specific Aims 
 
The specific objectives of this study are to develop a microfluidic large scale integration system that 
achieves the following: 
1. Time conservation: - to reduce the set-up time to less than thirty (30) minutes. 
 
2. Standardized system: - to have a standard set-up and fluidic manipulation system to allow 
access and use of more complex platforms that use hundreds of micro-valves. 
 
3. User-friendliness: - to enable unskilled personnel to flawlessly set-up and run a microfluidic 
system. 
 
4. Portability: - to enable the mobility and implementation of microfluidic large scale integration 






3.4 Conceptual Framework 
 
To achieve the aims of this research project, we will investigate several approaches to solve existing 
challenges on the current microfluidic systems. 
A key reason for the long duration of chip set-up is the need to manually fill each control line with 
water independently using material shown in Figure 3.1 (a) and a dispensing syringe and then placing 
the control pins into the chip individually during the chip preparation. After the insertion of pins, the 
system will represent that shown in Figure 3.1 (b). A connection of each of the control channels to its 
respective pressurized line is to be made by connecting each control channel to its individual port on 
the pressure manifold as shown in Figure 3.2. This process coupled with the insertion of pins is 
prohibitively laborious as a lot of time is required for the set-up (6 hours to an entire day) and this 
requires the meticulous attention of highly trained personnel. 
The first step of our new approach will be to investigate and develop ‘microfluidic plugs’ to 
incorporate multiple control pins into the chip simultaneously as shown in Figure 3.3. 
The second step of our new approach will be to investigate the possibility of moving MSLI systems 
from a manual loading process during chip preparation to an automated loading process. Basically, 
the second step seeks to automate the off-chip to on-chip fluid transport. 
The third step will be to investigate the possibility of miniaturization of the pressure and valve control 
module shown in Figure 3.4 that harbours the pressure manifolds (shown in Figure 3.2) into a portable 


















Figure 3.1: (a) Picture showing a microfluidic stainless steel stub (top), tygon tube (middle) and 
luer stub adaptor (bottom). Both the stub and the adaptor have a 23 gauge blunt-end stainless 
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Figure 3.4: The pressure and valve control module. It is connected to the computer via an 
ethernet communication cable. This module comprises of a series of 8-port pneumatic pressure 














The microfluidic system developed in this project consisted of an Olympus CKX41 inverted 
trinocular head microscope. The imaging was done using the Olympus UPlanFL N 4X/0.13PhP and 
Olympus CAch N 10X/0.25Php objectives. Images captured and movies recorded were performed 
using the Olympus SC 30 and Olympus SC 100 colour digital cameras. The Olympus SC 30 camera is 
most suitable for live inspection and movie recording (It has a full resolution mode that offers 10 
images per second at 3.2 megapixel resolution) while the Olympus SC 100 is most suitable for 
documentation (It is capable of capturing 10.6 megapixels with each single snapshots for 
unprecedented resolution at low magnification) [99].  The imaging was performed using Analysis 
getIT v 5.1, imaging software developed by Olympus Soft Imaging solutions GmbH. 
4.1.2 Multilayer Soft-Lithography. 
Multilayer Soft-lithography (MSL) offers a low cost technique of fabricating polydimethylsiloxane 
(PDMS) microfluidic devices with on-chip microvalves for automated and precise control of fluid 
flow [95]. The device described in this project was fabricated using the multilayer soft-lithography 
developed by the Quake research group, this was explained in detail in a previous chapter. The same 3 
step microfabrication process of soft-lithography described in a previous chapter, was used.  
For the concept development step, device designing was done with a computer-aided design (CAD) 
program (AutoCAD® software in particular). For the rapid prototyping step, the photomask was used 
to perform photolithography. Positive or negative photoresist was spun coated on a clean silicon wafer 
at specified thicknesses as required for each of the designed features and exposed to UV light. For the 
replica molding step, the process involved the casting of a transparent, silicone-based liquid pre-
polymer, against the master mold using an elastomeric material (PDMS in particular) to generate a 





4.1.2.1 Multi-layered Soft-lithography Device fabrication protocol/method. 
In the first step of device fabrication, the device was designed using Autodesk AutoCAD® 2014 
software and the completed design was then sent to fabricating services such as The Stanford 
microfluidics foundry at Stanford University, USA [100] or printing services such CAD/Art Services 
Inc. in the USA. After this step, PDMS master molds and PDMS microfluidic device fabrication 
processes were performed. The procedures are presented in this sub-section. These processes were 
performed in the laboratory’s clean room facility. A clean room is a specially designed laboratory 
where the size and the number of airborne particulates are highly controlled, together with the 






















PDMS Master Mold Fabrication Procedure 
 
For the work described in this dissertation, the actual process parameters used in the fabrication of the 
microfluidic device master molds is presented in Appendix A. 
Materials and Equipment 
 4” Silicon wafers 
 Wafer tweezers 
 Negative photoresist - SU-8 2010 from Microchem Corp., USA 
 Negative photoresist developer - SU-8 developer from Microchem Corp., USA 
 Positive photoresist  - MAP 1275 from Microchem Corp., USA 
 Positive photoresist (MAP 1275) developer  - ma-D 531 from Microchem Corp., USA 
 Isopropyl alcohol 
 Deionized water 
 Silanizing agent -  hexamethyldisilazane (HMDS) and trichloromethylsilane (TCMS) from 
Sigma-Aldrich® Corp., USA 
 Cleaning Solution – Micro-90 solution 
 Transparency mask – clear glass plate 
 Photomasks - CAD/Art Services Inc. (USA) printed masks on emulsion film. 
 3 or 4 hot plates 
 Laboratory oven 
 Sample shaker or rocker –  
 Vacuum pump and desiccator – Wirsam Scientific & Precision Equipment (South Africa) 
desiccator. 
 Spin coater  - Laurell Technologies Corp.® WS-650Hz-23 Spin coater, equipment used to 
create a layer of specific height of un-cross-linked photoresist on a silicon wafer by spinning 
the substrate 
 Mask aligner - SUSS MicroTec MJB4, equipment used to cross-link the photoresist by 
exposing the photoresist through the aligned photomask to UV light. 
 Profilometer – KLA-Tencor D-120 profilometer, equipment used to measure widths and 








1. Cleaning transparency mask: - The transparency mask (clear glass plate) is inspected for 
scratches and if scratches are absent, it is then cleaned with a cleaning solution (Micro -90 or 
isopropyl alcohol) to remove any surface particulates and rinsed off with clean water. It is 
then dried using an air gun. When clean, the photomask of a single layer is attached to the 
transparency mask and installed on the Mask Aligner in preparation for exposure stage. 
N.B.: Each pattern of the photomask should be attached to its own clean transparency mask. 
 
2. Cleaning silicon wafers: - Prior to starting the master mold fabrication process, it is important 
to ensure the silicon wafers are clean. This can be done by placing wafers in a bubbling 
piranha solution (1:3 sulphuric acid and hydrogen peroxide) for 10 minutes [92]. Afterwards, 
wafers should be rinsed with deionized water and dried using nitrogen gas. The cleaned 
wafers should then be placed on a hotplate for 15 minutes at 200 °C to evaporate any residual 
humidity [92]. After the heating process, let the wafer cool at room temperature before 
proceeding to the next step. 
 
3. Spin coating photoresist: - According to desired height and feature profile (i.e. rectangular or 
rounded geometric profile) of the device, spin coat the silicon wafer with photoresist 
(negative photoresist for rectangular geometric profiles and positive photoresist for rounded 
geometric profiles). Spin time, speed and acceleration should be taken into account when 
using the spin coater to achieve the desired layer coat thickness. Layer thickness is inversely 
proportional to spin time, speed and acceleration [4]. 
 
4. Soft-bake or Prebake: - Bake the spin-coated wafer on a hot plate at 65 °C and 95 °C for the 
amount of time specific with manufacturer’s instructions for coatings of your desired 
thickness. Times can be as short as a couple of minutes (layers < 5 µm thick) or as long as 
hours (layers > 200 µm thick) [4]. After the bake, let the soft-baked wafer cool at room 
temperature before the next step. 
5. Exposure: - According to the light intensity provided by the mask aligner and the thickness of 
your coating, certain exposure energy is required as specified by manufacturer’s instruction. 
In practice, the light intensity of the mask aligner is usually fixed and the exposure energy can 
be varied by changing the exposure time [4]. 
 
6. Post exposure bake: - After exposure, depending of the nature of the wafer (i.e. negative 




hot plate at 65 °C and 95 °C for the amount of time specific with manufacturer’s instructions 
for coatings of your desired thickness. Positive photoresist spin-coated wafers do not require a 
post exposure bake step. After the bake, let the wafer cool at room temperature before the 
next step. 
 
7. Development: - Immerse the wafer into a container with photoresist developer and gently 
move or agitate the container around to mix the solution. Development times range from a 
few minutes (for layers thinner than 10 µm) to hours (for layers more than 400 µm thick) and 
the movement/agitation is usually done manually or using a shaker at an agitation rate of 60 
Hz [4]. After development, thoroughly dry the wafer using an air gun and inspect the wafer 
on a microscope to determine if all desired features are visually observable and to determine 
if the master mold is useable for the PDMS device fabrication process or replica molding 
step. 
 
8. Profiling: - Using a profilometer device, a measurement of the widths and heights of 
photoresist features on silicon wafers is performed to verify if the desired dimensions and 
channel profile (rectangular or rounded profile) on the master molds have been obtained. 
 
9. Mold reflow: Only applies to positive photoresist spin-coated wafers. After the profiling step, 
bake the wafer on a hot plate at 65 °C and 95 °C for the amount of time specific with 
manufacturer’s instructions for coatings of your desired thickness. After the bake, let the 
wafer cool at room temperature before profiling it again to check if the channel geometry is 
rounded. 
 
10. Hard-Bake: This is one of the last steps that removes any casting solvent residue such as 
photoresists and development solvents. Bake the wafer in an oven. Hard baking temperatures 
frequently range from 120 °C to 150 °C and baking times are usually longer than those used 
in the soft-bake step. After the bake, let the wafer cool at room temperature before proceeding 
to the final step. 
 
11. Silanization: - This is the last step, place the wafer and an open glass vial with small amount 
of silanizing agent in a desiccator and apply vacuum for a few minutes and turn it off and 






PDMS Microfluidic Device Fabrication Procedure 
 
For the work described in this dissertation, the actual process parameters used in the fabrication of the 
PDMS microfluidic device is presented in Appendix A (push-up valve configuration) and Appendix B 
(push down valve configuration). 
Materials and Equipment 
 Master mold (finished product of the PDMS master mold fabrication process that contain the 
photoresist features) 
 Vacuum pump and desiccator – Wirsam Scientific & Precision Equipment (South Africa) 
desiccator. 
 Spin coater  - Laurell Technologies Corp.® WS-650Hz-23 Spin coater, equipment used to 




 Laboratory oven 
 Scalpel and razor blades 
 Scotch tape 
 Plastic petri dishes 
 Glass slides or cover slips 
 Microscope 
 Wafer tweezers 
 Planetary centrifugal mixer - Thinky Corp., USA, ARE-250CE planetary centrifugal mixer 
model. 
 Silanizing agent - hexamethyldisilazane (HMDS) and trichloromethylsilane (TCMS) from 
Sigma-Aldrich® Corp., USA 
 PDMS – Momentive RTV615 044-PLBX Kit obtained from RS Hughes™, Sunnyvale, USA. 









1. Cleaning master mold wafer: - To ensure easy PDMS release, all master molds are to be 
silanized by exposing them to a salinizing agent in an air tight container for a few minutes.  
 
2. PDMS mixing: - Weigh the desired amount of PDMS pre-polymer in a disposable or re-
usable plastic cup. Pour in the appropriate amount of the cross-linker according to the desired 
final elastomer stiffness (e.g. 10:1 elastomer base to cross-linker base of the PDMS kit). Mix 
the PDMS using a planetary centrifugal mixer which has been adjust according to 
manufacturer’s instructions for the desired mixture properties.  
 
3. Flow layer PDMS casting: - Each flow layer master mold (placed in an aluminium foiled 
covered petri dish) is then coated with an appropriate amount of PDMS mixture to obtain the 
desired layer thickness. 
 
4. Control layer PDMS casting and glass slide/ cover slip coating: - According to desired height 
and feature profile of the device, spin coat the control layer master mold with an appropriately 
mixed PDMS mixture (usually 20:1 elastomer base to cross-linker base). Spin time, speed and 
acceleration should be taken into account when using the spin coater to achieve the desired 
layer coat thickness. 
 
5. De-gassing/ de-bubbling: - PDMS on the flow layer master molds is then degassed in a 
desiccator under vacuum for 60 minutes or until all bubbles have disappeared.  
 
6. Soft-bake: - PDMS coated glass slides or cover slips and both flow layer and control layer 
molds are then placed in an oven for baking. The soft-bake is done at 80 °C. Baking times can 
be shorter (up to 40 minutes) for thinner layers and longer (up to 60 minutes) for thicker 
layers.  
 
7. Alignment: - Following baking, PDMS flow layers are peeled from the molds and cut to size 
using a razor blade or scalpel. Flow channel access ports are then created using a punch press. 
The punched flow layers are then aligned onto the PDMS spin-coated and soft-baked control 





8. PDMS bonding: - Following alignment, the aligned devices are soft-baked for about an hour 
at 80 °C in an oven. After the soft-bake, the bonded device is then cut and peeled off the 
control layer mold and access ports to the control layer are created using a punch press.  
 
9. Substrate bonding: - The multi-layered bonded device is then placed on a cured PDMS coated 
glass slide or cover slip and placed in an oven at 80 °C for several hours (usually 9 – 12 























4.2 Chip Designs 
The device designing was done using Autodesk AutoCAD® 2014 software. When designing the chip, 
several design specifics were taken into account, such as sizes of channels (i.e. height and width), type 
of channels (i.e. rectangular or rounded), feature architecture (i.e. push up or push down valves) and 
finally the function of the device (i.e. requirements of micropumps, micromixers or rotary channels. 
The completed design was then sent off to CAD/Art Services Inc. in the USA for high-resolution 
printing, 40 000 dots per inch (dpi) on transparency and the resultant transparency were the 
photomasks used for fabricating the device using the fabrication protocol explained above in section 
4.1.2.1. 
Three microfluidic devices/chips were fabricated and used in the work described in this dissertation, 
and these are: 
A. Dual Port Microfluidic Chip. 
 
This microfluidic device shown in Figure 4.1, is comprised of two PDMS layers bonded to a glass 
microscope slide. The device has normal microvalves with push-up functionality throughout the 
entire device and it has no sieve valves. The flow layer (comprising of flow channels used for 
biological assay transport) is bonded on top of the control layer (comprising of control channels 
which control the opening and closing of the microvalves for on-chip fluid manipulation) which 
in turn is bonded to a glass microscope slide with a thin PDMS layer to separate the two layers. 
These two layers are presented in Figure 4.2.  
In the microfluidic device, the control layer contains channels that are 10 µm high and 50 µm 
wide with rectangular geometry. The flow layer contains channels that are 10 µm high and 100 
µm wide with rounded geometry. The microfluidic device has two inter-connected access ports 
per control line, one on opposite ends of the chip (i.e. left hand side port connected to respective 
right hand side port) as shown in Figure 4.2 (a). The control line access ports are arranged in a 
‘zigzag’ pattern. Because of this architectural layout, the chip derives its name, “dual port” 
microfluidic device. The microfluidic device has a rotary flow channel (also referred to as a 
reactor channel/ reactor ring) which is to be used where continuous flow mixing is required and 
this is shown in Figure 4.2 (b). There are six flow access ports for every reactor channel as shown 
also in Figure 4.2 (b). 
The device’s design features also includes a rotary and linear pneumatic peristaltic micropumps 
shown in Figure 4.3 (a) and Figure 4.3 (b) respectively. The overall geometry of the combination 




biological experimentation that requires pumping of fluids (using a linear peristaltic pump) into a 








































Figure 4.2: The individual layers of the dual port microfluidic chip: (a) shows the bottom PDMS 
layer, the control channels presented in the green colour; (b) shows the top PDMS layer, the 
flow channels presented in the red colour. It’s a push-up valve configuration design. 
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Figure 4.3: (a) - Rotary pneumatic peristaltic micropump, also considered to be micromixer in 












Figure 4.4: The microfluidic chip geometry showing the designed combination of the linear and 
rotary peristaltic micropump. 




B. Single Port Microfluidic Chip. 
This microfluidic device shown in Figure 4.5, is comprised of two PDMS layers bonded to a glass 
microscope slide. The device has normal microvalves with push-up functionality throughout the 
entire device and it has no sieve valves. The device architecture and features are exactly the same 
as that of the dual port microfluidic chip. The two layers of this microfluidic device are shown in 
Figure 4.6. The device is called a ‘single’ port microfluidic chip because it has one port per 
control line. This is the only difference between the dual port and single port microfluidic chip. 
The device’s design features also includes a rotary and linear pneumatic peristaltic micropumps 
shown in Figure 4.3 (a) and Figure 4.3 (b) respectively. The overall geometry of the combination 

































Figure 4.6: The individual layers of the single port microfluidic chip: (a) the control channels 
presented in the green colour; (b) shows the flow channels presented in the red colour. It’s a 
push-up valve configuration design. 
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C. Hybrid Dual Port Microfluidic Chip. 
 
This microfluidic device shown in Figure 4.7, is comprised of two PDMS layers bonded to a glass 
microscope slide. The device has normal microvalves with push-down functionality throughout 
the entire device and it has no sieve valves. The control layer (comprising of control channel 
which control the opening and closing of the microvalves for on-chip fluid manipulation) is 
bonded on top of the flow layer (comprising of flow channels used for biological assay transport) 
which in turn is bonded to a glass microscope slide with a thin PDMS layer to separate the two 
layers. These two layers are presented in Figure 4.8. 
In the microfluidic device, the control layer contains channels that are 10 µm high and 50 µm 
wide with rectangular geometry. The microfluidic device has two inter-connected ports per 
control line on the same side of the device i.e. on the left hand side. These ports are also aligned 
in a ‘straight’ pattern as shown in Figure 4.8 (a) different to the ‘zigzag’ pattern used on the dual 
and single port microfluidic devices. This device has a control line access port architectural layout 
that maintains a dual port functionality. The dual port functionality is maintained in the sense that 
the two ports are interconnected by a 10 µm high and 100 µm wide bridging channel. Because of 
these modifications, the microfluidic device is called the ‘hybrid’ dual port microfluidic device.  
The flow layer contains channels that are 10 µm high and 100 µm wide with rounded geometry. 
The device maintains the six flow channel access port per reactor channel like the two previously 
discussed devices. These access ports are also aligned in a ‘straight’ pattern on the opposite end of 
the control line access ports, different from the flow channel access port layout found in the dual 
and single port devices. 
The device’s design features also includes the rotary and linear pneumatic peristaltic micropumps 
shown in Figure 4.3 (a) and Figure 4.3 (b) respectively. The overall geometry of the combination 















Figure 4.8: The individual layers of the hybrid dual port microfluidic chip: (a) shows the top 
PDMS layer, the control channels presented in the green colour; (b) shows the bottom PDMS 















4.3 Plug Designs 
 
A key reason for the long duration of a microfluidic device set-up work flow is the need to manually 
fill each control line with water independently using a dispensing syringe and placing the control pins 
into the microfluidic device one at a time. After the insertion of pins, a connection of each of the 
control channel to its respective pressurized line is the made by connecting each control channel to its 
individual port on the pressure manifold. This process coupled with the insertion of pins is 
prohibitively laborious as a lot of time is required to set-up (6 hours to an entire day) and requires the 
meticulous attention of a highly trained personnel. 
The first step of the new approach will be to investigate and develop ‘microfluidic plugs’ to 
incorporate multiple control pins into the chip simultaneously as shown in Figure 4.9. In the work 
described in this dissertation, two different microfluidic plugs were designed and developed to be 
compatible with the commonly used tubing (0.02” OD X 0.06” ID, acquired from Cole Parmer, UK) 
for microfluidic applications. 
The two developed plugs are: 
1. Polymethyldisiloxane (PDMS) Microfluidic Plug 
 
This microfluidic plug was made using the same material used to make the microfluidic 
device, polymethyldisiloxane (PDMS). The microfluidic plug is a PDMS monolayer 
fabricated using the control layer master mold in the same manner the microfluidic device’s 
control layer was made. Using a razor blade or scalpel, the PDMS control layer was trimmed 
or cut around the control line access ports; the cut area on the PDMS control layer is 
highlighted in Figure 4.10. The cut pieces (left hand side and right hand side rectangular 
pieces) where then punched in alignment to the access port pattern appearing on the surface to 
enable the plug to be easily matched on the microfluidic device when inserting the plug. 1” 
steel pins (0.025” OD X 0.013” ID X 1” long steel pins, acquired from New England Small 
Tube Corporation, UK) were then inserted through the punch ports. To hold the pins in place, 
a small layer of epoxy adhesive (Loctite M-31CL Hygol Medical Device Epoxy Adhesive) 








2. Epoxy Adhesive Microfluidic Plug 
 
The microfluidic plug was made using an epoxy adhesive (Loctite M-31CL Hygol Medical 
Device Epoxy Adhesive) and 1” steel pins (0.025” OD X 0.013” ID X 1” long steel pins, 
acquired from New England Small Tube Corporation, UK). The epoxy microfluidic plug was 
made by using a microfluidic device and a PDMS monolayer of the control layer. The PDMS 
monolayer was cut around the control line access ports as highlighted in Figure 4.10, and the 
PDMS monolayer was left with hollow sections. It was then placed and aligned on top of the 
microfluidic device which has the 1” steel pins protruding from it. Once aligned, epoxy 
adhesive was carefully poured into the hollow sections and left to dry for 24 hours. After the 
epoxy was dried, the PDMS monolayer was peeled off the cured epoxy leaving the epoxy 

























Figure 4.9: Diagram showing the main difference between the old system of inserting pins and 

















        
The old system whereby each 
control line is filled with water and 
independently incorporated into the 
chip. 
The new system whereby all control 
lines are bound together using a plug. 
The entire plug is incorporated into the 









Figure 4.10: Diagram showing the trimmed sections of the PDMS microfluidic device’s control 
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4.4 Auto-loading System 
 
4.4.1 Background and Significance. 
 
One of the first commercially available laboratory automation platforms was developed by Skeggs 
and published in 1957 and made commercially available by Technicon Corporation [101]. The first 
machines, the Autoanalyzer utilized continuous flow analysis in which a continuous stream of fluid 
was divided into segments by air bubbles. The air bubbles were introduced into the stream to maintain 
separation between samples [101]. These first machines were successful and gave satisfactory 
analytical results of blood urea or glucose at the rate of up to 40 samples per hour [101]. While these 
systems were a significant advancement in laboratory automation, the serial processing and analysis 
design limited throughput.  
The 1950s brought about the emergence and common use of microtiter plates which eventually made 
a significant impact on the standardization of laboratory automation. Microtiter plates enable parallel 
processing of clinical samples for high throughput analysis in molecular diagnostics assays such  as 
enzyme-linked immunosorbent assay (ELISA) and those used in polymerase chain reactions (PCR) 
and the most common automated molecular diagnostics tests often utilize robotic sample handling 
systems compatible with 96-well plates [102]. These robotic arms can be programmed to dispense or 
withdraw reagent, control temperature, mix solutions by shaking and transport microtiter plates 
between locations [102]. 
Since the introduction of the multilayer soft-lithography (MSL) as one of the most convenient ways of 
fabricating complex microfluidic devices consisting of a vast network of channels, valves, mixers and 
pumps in the early 2000s, great advances have been witnessed in the microfluidics field especially in 
the Microfluidic Large Scale Integration (MLSI) platform. To date, selected automated microfluidic 
devices have been developed, and a variety of microfluidic instruments used for nuclei acid and 
protein electrophoresis analysis are now commercially available [103]. However, these instruments 
are currently constrained from being popularized in common laboratories due to their high cost of 
purchase and maintenance. 
Most MLSI based microfluidic devices still require the traditional manual preparation procedure 
making it impractical for microfluidic devices with a high on-chip operation complexity to be used for 
either scientific research or point-of-care diagnostics. When the fluid transport during the microfluidic 
device preparation step is automated, fast and precise fluid operation can be anticipated and some of 
the existing biased malfunction problems existing in the manual set-up can also be eliminated. An 




microfluidic devices can provide an efficient, low-cost maintenance and portable solution to 




























4.4.2 Automation (Auto-loading) Characterization. 
 
Microvalves and micropumps on the microfluidic device/chip automate the transport of samples and 
reagents to various locations on a device for processing and analysis. The multi-layered soft-
lithography fabricated microvalves, Quake valve [3], use a fluid, usually de-ionized water in the 
control channels. Pressure is applied in the control channels to close a valve and no pressure is applied 
to open a valve. This is how an off-chip pressure source opens and closes valves. 
The on-chip fluid handling has been successfully developed and being deployed in many applications. 
However, there is a technological gap between off-chip fluid handling/transport and on-chip fluid 
handling, and for this reason most MLSI based microfluidics system are impractical to use in POC 
setting. The main issue is that there is need to form a physical connection (i.e. off-chip to on-chip 
interface) to deliver fluid into the control channels in a quick, safe and efficient way. This is important 
if we are to have a fully automated MLSI system that offers an automated handling of control channel 
fluid in the device preparation step with minimal human involvement. When this system is extended 
to the flow channels, it will also provide an automated biological auto-sampling system for off-chip to 
on-chip sample transport. 
The off-chip to on-chip fluid transport is automated by making use of electrically actuated valves. We 
used a multi-position, dead-ended flow path, universal electrical actuated, high torque valve (EUTA-
2CSD16MWE) which can be simply referred to as the SD valve and a multi-position, flow-through 
flow path, universal electrical actuated, high torque valve (EUTA-2CSF16MWE) which also can be 
simply referred to as the SF valve were procured from VALCO Instruments Company Inc. a company 
based in Switzerland.  
The SD valve selects one of the 16 flow path streams. A stream refers to a flow path. The selected 
stream flows from the outlet to either another sampling valve, pressure sensor, liquid detector or 
microfluidic device etc. The same flow path can be used to direct one stream to a number of outlets. 
The schematic of this valve is shown in Figure 4.12. While the SD valve selects and isolates one of 
the 16 streams, with the remainder dead-ended, the SF valve works in a similar way but with a minor 
difference. The distinction between the SD and SF valves is that, for the SF valve, the non-selected 
streams allow flow through individual outlets. This is shown in the schematic in Figure 4.13. 
The control of the electrically actuated valves was done using a computer. The connection to the 
computer was established using an RS-232 interface. The RS-232 input commands were transmitted 
to the device via a custom built graphical user interface software. We also had VALCO Instruments 
company Inc. custom make 2.3 mm diameter hose-barb SD and SF adapters for use with 3/32” (ID) X 







Figure 4.12: 8 position dead-ended flow path – SD configuration valve schematic. S1 – S8 denote 
the stream/port number. A stream/port refers to a flow path. If the stream (green flow paths) 
are not connected to a selector (red ring), those streams are dead-ended. When a stream is dead-
ended, it implies that fluid cannot flow in/out of that stream because there is no bridging 
connection. In this schematic, the non-selected streams (except S5) are all dead-ended while 
stream S5 is open because it is connected to the selector thus allowing flow of fluid to either 
another sampling valve, pressure sensor, liquid detector or microfluidic device via the selector’s 














Figure 4.13: 8 position flow-through flow path – SF configuration valve schematic. S1 – S8 
denote the stream/port number. A stream/port refers to a flow path. If the streams (green flow 
paths) are not connected to a selector (red ring), those streams allow flow of fluid to their 
individual outlets. In this schematic, the non-selected streams (except S5) are all allowing flow 
through of fluid to their individual outlets. The selected stream, stream S5 in this case is 
connected to the selector (thereby breaking the connection to its individual outlet), is allowing 
flow of fluid from the stream intake port to either another sampling valve, pressure sensor, 
liquid detector or microfluidic device via the selector’s stream outlet port. The image was 








4.5 Graphical User Interface Software 
 
To maximize the automation platform consistency and modularity, each of the two automated 
platforms is controlled by a common, distributed application suite that was developed in LabVIEW. 
LabVIEW, which stands for Laboratory Virtual Instrumentation Engineering Workbench is a 
graphical programming language first released in 1986 by National Instruments Corporation (USA). 
LabVIEW implements a dataflow paradigm in which the code is not written like in most traditionally 
programming languages, but rather drawn or represented graphically similar to a flow chart diagram 
[105]. Program execution follows connector wires linking processing nodes together [105]. Each 
function or routine is stored as a virtual instrument (VI) having three main components: the front 
panel which is essentially a form containing inputs and controls and can be displayed at run time, a 
block diagram where the code is edited and represented graphically and a connector pane which 
serves as an interface to the VI when imbedded as a sub-VI [105]. LabVIEW compiles the code as it 
is created thereby providing immediate syntactic and semantic feedback and reduces the time required 
for development and testing. For this reason, it is an appropriate programming platform for integrated 
automation systems for benchtop applications and even larger automation integrated system for rapid 
prototype development. One of many advantages LabVIEW has over other programming languages is 
that memory allocation/deallocation is automatically managed by LabVIEW [105]. 
The main graphical user program that is used in this work for microfluidic device microvalve 
automated control was developed using LabVIEW. The main VI program has been named ‘MagicElf’ 
and the front panel is shown in Figure 4.14. The automation of the loading valves for the microfluidic 
device described in this work was done by a sub-VI we created and incorporated into the main VI 






Figure 4.14: A screenshot image showing the front panel of the main LabVIEW VI (MagicElf) 




















Figure 4.15: A screenshot image showing the sub-VI control board that controls the automated 
fluid transport system from off-chip to on-chip. This automation is performed by the aid of the 
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CHAPTER 5: RESULTS AND DISCUSSION 
 
5.1 Microfluidic Plugs 
 
One of the objectives of this project was to develop microfluidic plugs to relieve technicians from 
inserting pins into the microfluidic chip individually during the chip preparation step. These 
microfluidic plugs are supposed to be used in conjunction with an auto-loading system as off-chip to 
on-chip control channel interfaces. Two microfluidic plugs were developed and the following are the 
performance results of each of the fabricated plugs. Depending on the performance results and 
usability of the microfluidic plugs as off-chip to on-chip control channel interfaces, the same concept 
idea and design can be extended for use as off-chip to on-chip flow/reagent channel interfaces. 
Polymethyldisiloxane (PDMS) Microfluidic Plug: 
These microfluidic plugs were made from polymethyldisiloxane (PDMS). The fabricated device did 
not work as expected, the summary of the problems identified while using the device is given below: 
The PDMS plug was not rigid enough (i.e. it was too soft/flexible) to be used as a plug. Because of 
the non-rigidness of the plug, it did not tightly hold the steel pins in place and it also made handling of 
the plug very difficult during the insertion of the plug into the microfluidic chip. Even when insertion 
of the plug into the chip was successful, during the process of removing the plug from the chip, the 
plug itself was destroyed as pins would either remain inserted into the chip or tear the PDMS block 
along the handled surfaces. This limited the plug to once-off use. We attempted to increase the 
rigidness of the plug by increasing the elastomeric stiffness (using different PDMS mixing ratios for 
the elastomer base to cross-linker base) and plastering it with epoxy adhesive and both attempts 
neither improved the rigidness nor the quality of the plug. We thus concluded that PDMS was an 











Epoxy Adhesive Microfluidic Plug: 
This microfluidic plug was made from epoxy adhesive. The fabricated device worked as expected, 
and became the first prototype plug for the auto-loading system. The device offered better rigidness 
(for holding the steel pins tightly in place) and handling than the PDMS plug. It also proved to be 
strong and durable for multiple uses over a period of time. Even though the epoxy plug worked as 
expected, as the first prototype, it exhibited some design flaws during operation which needed 
solutions in the foreseeable future. A summary of the problems identified while using the device is 
given below: 
Often there was difficulty in inserting the plug into the microfluidic chip because of the slight 
misalignment of the plug’s pins and the microfluidic chip’s access ports. We identified the punching 
procedure during the microfluidic chip fabrication process as the main reason for the misaligned plug 
to chip connection. During the microfluidic chip fabrication process, each access port is punched one 
at a time using a punch. Precision is lost this way as it is nearly impossible to punch each of the access 
ports on different microfluidic chips, identically on the same exact spot. Also, since the epoxy plug is 
made using a microfluidic chip, it turns out that, the epoxy plug’s pin separation is unique to the chip 
used during the fabrication process. An attempt to use the plug on a different microfluidic chip, 
resulted in a slight misalignment between the plug’s pins and the access ports on the chip and 
delamination (i.e. separation of the bonded PDMS layers and the glass substrate) occurred during 












5.2 Auto-loading System Version 1.0 
 
Auto-loading system version 1.0 (v1.0) was the first system developed to automate the loading 
process of the control channels on a microfluidic device. For this version of the system, the 
microfluidic device used was the ‘dual port’ microfluidic chip. This system is shown in Figure 5.1. 
5.2.1 System Characterization. 
 
The experimental set-up of the system was done according to the schematic illustration presented in 
Figure 5.1. The system is comprised of a 16 multi-position SF valve, 16 multi-position SD valve, fluid 
reservoir container, fluid waste container, pressure and valve control module, two microfluidic plugs, 
dual port microfluidic chip and a computer. The pressure and valve control module that shown in 
Figure 5.2 and is connected to the computer via an ethernet communication cable. This module 
comprises of a series of 8-port pneumatic pressure manifolds connected to pneumatic pressure 
regulators and a pneumatic pressure source (air compressor). The SF and SD valves are connected to 
the computer via RS-232 communication cables. The size of the tubing used for pressure and valve 
control module to the fluid reservoir container, fluid reservoir container to SF valve, SD valve to fluid 
waste container was 3/32” (ID) X 5/32” (OD). The connection between the SF valve to microfluidic 
plug and microfluidic plug to SD valve was done using 0.02” (OD) X 0.06” (ID) tygon tubing. The SF 
valve is used as a fluid injector device and the SD valve is used as a fluid receiver device. The 
microfluidic plugs connected to both the SF and SD valves have been inserted into the dual port 
microfluidic chip. Each control line on the microfluidic chip has its own individual stream/port on 
both the SF and SD valves.  
The selectors on both the SF and SD valves have two inter-connected ports. For the SF valve, each 
stream has its inlet connected to the control channel on the microfluidic chip via the microfluidic plug 
and its individual outlet is used as an pressure inlet (the SF valve allows bidirectional flow between 
the inlet and its individual outlet) implying that it is connected to a port on the pressure manifold 
found on the pressure and valve control module. The SF valve’s selector will have one of its ports as a 
common fluid inlet (for fluid flow from the fluid reservoir container) and the other as an outlet in the 
case where stream/port selection has occurred. For the SD valve, each stream is connected to the 
corresponding control channel that is also connected to the SF valve via a microfluidic plug. The SD 
valve’s selector will have one of its ports as a fluid inlet in the case where stream/port has occurred 
and the other will be a common outlet (for flow to the fluid waste container).  At rest position shown 
in the red state, there is no stream selection on both the SF and SD valves, for the SF valve, each 
stream is inter-connected to its own pneumatic pressure inlet and for the SD valve, the corresponding 




During the automation process, the developed user-friendly operating system (MagicElf) on the 
computer sends commands to the pressure and valve control module, SF and SD valves. MagicElf 
actuates the SF and SD valves for stream position change and actuates the individual solenoid valves 
residing in the pressure manifolds to open and close microvalves. In synchronization, the SF and SD 
valves actuate to a selected valve position and stream selection on matching streams on both the SF 
and SD valves occurs. Milliseconds later, pneumatic pressure from the pressure and valve control 
module is applied to the fluid reservoir container enabling flow of fluid from the container into the SF 
valve via the selector (shown in the green configuration in Figure 5.1) into the selected stream port 
and then flows into the chip’s control line via the microfluidic plug. The introduced fluid in the 
control line will then flow through the chip and come out at the opposite end of the chip into the SD 
valve (shown in the green configuration in Figure 5.1) via another microfluidic plug. The fluid 
continues to flow through the SD valve until it reaches the fluid waste container. The instant fluid is 
collected in the fluid waste container, in synchronization, the SF and SD valve actuate to the next 
valve position. During the actuation of the SF and SD valves, the following happens at the SF and SD 
valves: 
i. The connection between the selector and a selected stream’s inlet port is broken and the inter-
connection between that inlet and its individual pneumatic pressure inlet is re-established and 
the corresponding port on the manifold is switched on allowing pneumatic pressure to be 
applied through that inlet into the microfluidic chip’s control line. 
ii. While at the SD valve, the corresponding stream is dead-ended thus functionalizing the 
microfluidic chip’s control line (i.e. ability to open and close valves in that control line). 
When the SF and SD valves actuate to the next position, the process described above is repeated until 
all the control lines in the microfluidic chip have been functionalized. The operating pneumatic 
pressure was 20 pounds per square inch (psi). As a building step and for testing the prototype, the 
system actuates to the next valve position as instructed by an ‘elapsed time’ LabVIEW function that 
has been incorporated into the ‘MagicElf’ operating system. The actual elapsed time for valve 
actuation was manually measured using a stopwatch in one of the trial runs. It is the least measured 
and optimized time required for a control line to be functionalized specific to this current set-up. It 
can vary depending on tygon tubing length, operating pressure values, chip architecture and material 








5.2.2 Results and Discussion. 
 
Auto-loading system version 1.0 was able to automate the loading process however this system 
proved to be inefficient when compared to the manual set-up process. This auto-loading system was 
operating at a rate of more than 30 minutes per control line. This translated to about 390 minutes (6 
hours 30 minutes) for the 13 control line dual port microfluidic chip. The manual process for the same 
microfluidic chip has a rate of about 5 minutes per control line and depending on the mental and 
physical state of the technician the rate can decrease to about 10 minutes per control line for if the 
technician is mental fatigued. The manual process can take 65 minutes (1 hour 5 minutes) to 130 
minutes (2 hours 10 minutes) for a 13 control line microfluidic dual port chip. 
The key reason responsible for the inefficiency of the automated loading system was on-chip air 
introduction. We observed and determined that the auto-loading system was introducing air into the 
system (specifically to the microfluidic chip) ahead of the fluid. This air was being compressed in the 
tubing ahead of the fluid and then forced into the microfluidic chip and pushed all the way to the SD 
valve and into the fluid waste container.  This process of compressing the air off-chip and forcibly 
funnelling it on-chip ahead of the fluid played a key part in increasing the loading time for the system. 
At this point, a different approach to the auto-loading system was required or a quick and safe method 
of removing this introduced air in the system was required so as to have an efficient auto-loading 
system. One approach was to introduce robotic pipetting in the system in order to eliminate the 
chances of introducing air into the chip; however, this is a very expensive solution to the problem, one 
that is impractical if the auto-loading system is to be used along other microfluidic devices as point-









































































































atic illustration of the A
uto-loading System
 v1.0 using 4 m











































































5.3 Auto-loading System Version 2.0 
 
Auto-loading system version 2.0 (v2.0) was the second system developed as the most economical 
solution to the problem of inefficiency identified in the auto-loading system v1.0. This new system 
was designed to remove a large approximate volume of air off-chip by introducing small branches in 
the flow path. These small branches were in the form of custom made ‘tee’ steel pins (0.025” OD X 
0.013” ID X 1” long, Vita Needle Company, USA). For this version of the auto-loading system, tee-
pins were used in place of microfluidic plugs because the nature of the pins made it difficult to make 
useable plugs. This system also made use of the ‘single port’ microfluidic chip. This system is shown 
in Figure 5.3. 
5.3.1 System Characterization. 
 
The experimental set-up of the system was done according to the schematic illustration presented in 
Figure 5.3. The system is almost identical to auto-loading system v1.0 but with the following 
differences: 
i. Tee-pins were used in place of microfluidic plugs. 
ii. Single port microfluidic chip used in place of the dual port microfluidic chip. 
iii. The automation process is slightly different and this is explained in more detail below. 
During the automation process, the developed user-friendly operating system (MagicElf) on the 
computer sends commands to the pressure and valve control module, SF and SD valves. MagicElf 
actuates the SF and SD valves for stream position change and actuates the individual solenoid valves 
residing in the pressure manifolds to open and close microvalves. In synchronization, the SF and SD 
valves actuate to a selected valve position and stream selection on matching streams on both the SF 
and SD valves occurs. Milliseconds later, pneumatic pressure from the pressure and valve control 
module is applied to the fluid reservoir container enabling flow of fluid from the container into the SF 
valve via the selector (shown in the green configuration in Figure 5.3) and into the selected stream 
port and then flows to the tee-pin. At the tee-pin junction, the fluid and the air ahead of it flows to the 
SD valve. The reason for this occurrence is that, at the tee-junction, the flow path to the SD valve 
offers less resistance than the flow path to the microfluidic chip were it is compressed and forced into 
the chip. The introduced fluid and air will flow into the SD valve (shown in the green configuration in 
Figure 5.3). The fluid and air ahead of it continues to flow through the SD valve until it reaches the 
fluid waste container. The instant fluid is collected in the fluid waste container, only the SD valve will 
actuate to the next valve position. Since the SD valve has actuated, the flow path that had the fluid is 




junction, hence fluid (without air ahead of it) is then forced to flow into the microfluidic chip through 
the other end of the tee-pin that has been inserted into the chip. After the complete filling of the 
control line with fluid, the SF valve will then actuate to the next valve position. When the SF valve 
actuates, the connection between the selector and a selected stream’s inlet port is broken and the inter-
connection between that inlet and its individual pneumatic pressure inlet is re-established. The 
corresponding port on the manifold is then switched on allowing pneumatic pressure to be applied 
through that inlet into the microfluidic chip’s control line, thereby functionalizing the control line (i.e. 
ability to open and close valves in that control line). The functionalization of the microfluidic chip’s 
control line happened as follows; since, the SD valve was first to be actuated to the next valve 
position before the SF valve, the corresponding stream was dead-ended, to functionalize the 
microfluidic chip’s control line, the SF valve only needed to actuate to the next position and allow 
pneumatic pressure to be applied in that control line. 
When the SF and SD valves actuate to the next position, the process described above is repeated until 
all the control lines in the microfluidic chip have been functionalized. The operating pneumatic 
pressure was 20 pounds per square inch (psi). The system actuates to the next valve position as 
instructed by an ‘elapsed time’ LabVIEW function that has been incorporated into the ‘MagicElf’ 
operating system. The actual elapsed time for valve actuation was manually measured using a 
stopwatch in one of the trial runs. It is the least measured and optimized time required for a control 
line to be functionalized specific to this current set-up. It can vary depending on tygon tubing length, 















5.3.2 Results and Discussion. 
 
Auto-loading system version 2.0 was able to automate the loading of fluid off-chip to on-chip with 
efficiency when compared to auto-loading system v1.0 and the manual set-up process. This auto-
loading system was operating at a rate of 1 minute 30 seconds per control line. This translated to 
about 21 minutes for the 13 control line single port chip. Comparing this system to the manual set-up, 
which takes about 65 minutes (1 hour 5 minutes) for a 13 control line microfluidic single port chip, 
this automated system was saving 68% of the time required to prepare the microfluidic chip. The 
auto-loading system v2.0 was saving 95% of the time taken by its predecessor, the auto-loading 
system v1.0. 
The key reason responsible for the increased efficiency of the automated loading system was the 
successful removal of a large approximate volume of air off-chip before it was introduced on-chip. 
This was achieved by branching off the flow paths using tee-pins. The use of tee-pins did improve the 
automated loading system’s efficiency; however the use of tee-pins invalidated the use of microfluidic 
plugs, mainly because it was difficult to fabricate microfluidic plugs using tee-pins. Figure 5.4 shows 
a picture of the tee-pins that have been inserted in the single port microfluidic chip. To bring back the 
practicality of using microfluidic large scale integration systems for point-of-care medical diagnostics, 
microfluidic plugs are essential in reducing the set-up time. This led to a need for the development of 
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5.4 Auto-loading System Version 3.0 
 
Auto-loading system version 3.0 (v3.0) was the system developed to re-introduce the use of 
microfluidic plugs like those used in auto-loading system v1.0 and have the same air purging 
mechanism of auto-loading system v2.0 but without the use of tee-pins. For this version of the system, 
the microfluidic device used was the ‘hybrid dual port’ microfluidic chip. This system is shown in 
Figure 5.5. 
5.4.1 System Characterization. 
 
The experimental set-up of the system was done according to the schematic illustration presented in 
Figure 5.5. The system is almost identical to auto-loading system v2.0 but with the following 
differences: 
i. Microfluidic plugs were re-introduced in place of tee-pins. 
ii. Hybrid dual port microfluidic chip used in place of the single port microfluidic chip. 
During the automation process, the developed user-friendly operating system (MagicElf) on the 
computer sends commands to the pressure and valve control module, SF and SD valves. MagicElf 
actuates the SF and SD valves for stream position change and actuates the individual solenoid valves 
residing in the pressure manifolds to open and close microvalves. In synchronization, the SF and SD 
valves actuate to a selected valve position and stream selection on matching streams on both the SF 
and SD valves occurs. Milliseconds later, pneumatic pressure from the pressure and valve control 
module is applied to the fluid reservoir container enabling flow of fluid from the container into the SF 
valve via the selector (shown in the green configuration in Figure 5.5) and into the selected stream 
port and then flows into the chip’s control line via the microfluidic plug. The introduced fluid in the 
control line will then flow through the chip along the inter-port ‘bridge’ channel (shown in yellow on 
the microfluidic chip) that is between the two access ports. When it reaches the other access port, the 
same fluid movement observed in the case of branched flow paths using tee-pins occurs. The fluid 
will flow out of the chip via the other access port through the microfluidic plug and into the SD valve. 
The fluid and air ahead of it continues to flow through the SD valve (shown in the green configuration 
in Figure 5.5) until it reaches the fluid waste container. The instant fluid is collected in the fluid waste 
container, only the SD valve will actuate to the next valve position. Since the SD valve has actuated, 
the flow path that had the fluid is now dead-ended. The dead-end increases resistance in the flow path 
to the SD valve on the tee-junction, hence fluid (without air ahead of it) is then forced to flow into the 
microfluidic chip through the other end of the tee-pin that has been inserted into the chip. After the 




When the SF valve actuates, the connection between the selector and a selected stream’s inlet port is 
broken and the inter-connection between that inlet and its individual pneumatic pressure inlet is re-
established and the corresponding port on the manifold is switched on allowing pneumatic pressure to 
be applied through that inlet into the microfluidic chip’s control line, thereby functionalizing the 
control line (i.e. ability to open and close valves in that control line). The functionalization of the 
microfluidic chip’s control line happened as follows; since, the SD valve was first to be actuated to 
the next valve position before the SF valve, the corresponding stream was dead-ended, to 
functionalize the microfluidic chip’s control line, the SF valve only needed to actuate to next position 
and allow pneumatic pressure to be applied in that control line. 
When the SF and SD valves actuate to the next position, the process described above is repeated until 
all the control lines in the microfluidic chip have been functionalized. The operating pneumatic 
pressure was 20 pounds per square inch (psi). The system actuates to the next valve position as 
instructed by an ‘elapsed time’ LabVIEW function that has been incorporated into the ‘MagicElf’ 
operating system. The actual elapsed time for valve actuation was manually measured using a 
stopwatch in one of the trial runs. It is the least measured and optimized time required for a control 
line to be functionalized specific to this current set-up. It can vary depending on tygon tubing length, 


















5.4.2 Results and Discussion. 
 
Auto-loading system version 3.0 was able to automate the loading of fluid off-chip to on-chip in the 
same manner as auto-loading system v2.0. This auto-loading system was operating at a rate of 2 
minutes per control line. This translated to about 26 minutes for the 13 control line hybrid dual port 
chip. Comparing this system to the manual set-up, which takes about 65 minutes (1 hour 5 minutes) 
for a 13 control line microfluidic single port chip, this automated system was saving 60% of the time 
required to prepare the microfluidic chip. Although auto-loading system v2.0 was 30% more efficient 
than this system, auto-loading system v3.0 made use of microfluidic plugs, an essential component 
needed by the auto-loading system. The efficiency difference between auto-loading system v2.0 and 
auto-loading system v3.0 can be explained as follows: 
 Assuming there is no flow of fluid, the ‘tee’ steel pins of dimensions (0.025” OD X 0.013” ID 
X 1” long) used in auto-loading system v2.0 can approximately hold a volume of 2.18 𝑚𝑚3 
whereas the rectangular interconnecting bridge channel in the ‘hybrid dual port’ microfluidic 
chip used in auto-loading system v3.0 has dimensions (10 µm high, 100 µm wide and 1000 
µm long) thus it can approximately hold a volume of 0.001 𝑚𝑚3. We believe that this volume 
capacity difference in the sections of the auto-loading systems that aid the removal of trapped 
air, accounts for the difference in the efficiencies of these systems. We believe that even when 
flow of fluid is allowed, ‘tee’ pins of auto-loading system v2.0 allow more fluid to pass 
through than the interconnecting bridge channels of the ‘hybrid’ microfluidic chip hence 
making it more efficient than later. 
 We believe that as fluid flows through the rectangular interconnecting bridge channel in the 
‘hybrid dual port’ microfluidic chip used in auto-loading system v3.0, it encounters flow 
resistance in the form of friction between the fluid and channel surface. The same can be said 
for fluid flow in the ‘tee’ pins used in auto-loading system v2.0, however, we believe that the 
flow resistance and friction between the steel surface and the fluid is much smaller than that 
in auto-loading system v3.0 thus making auto-loading system v2.0 more efficient. 
Even though auto-loading system v3.0 was 30% less efficient, we concluded that this system, auto-
loading system v3.0 had met the objectives of the project because it made use of microfluidic plugs 
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5.5 Microfluidic Chips 
 
Important architectural features in the chip designs that were maintained in the microfluidic chips 
used in the auto-loading systems v1.0, v2.0 and v3.0 are the rotary pneumatic and linear peristaltic 
micropumps. The design images of these micropumps i.e. the rotary pneumatic and linear peristaltic 
micropumps were presented in Figure 4.3 (a) and Figure 4.3 (b) respectively. The figures below show 
these micrompumps on working fabricated PDMS microfluidic chips. Figure 5.6 and Figure 5.7 show 
the rotary pneumatic and linear peristaltic micropumps respectively. Figure 5.8 and Figure 5.9 show 





























Figure 5.6: One of the rotary pneumatic peristaltic micropumps found in all the three designed 
microfluidic chips in this project, i.e. dual port, single port and hybrid dual port microfluidic 
chips. The image above shows a partial view of the rotary flow channel and the chip achitectural 
























Figure 5.7: One of the linear pneumatic peristaltic micropumps found in all the three designed 
microfluidic chips in this project, i.e. dual port, single port and hybrid dual port microfluidic 
chips. The image above shows a partial view of the flow channel access port and the chip 
























Figure 5.8: ‘Open’ microvalves in a working microfluidic chip. This image shows a partial view 
of the a rotary flow channel and its respective rotary pneumatic peristaltic micropump. In the 
image above, no pneumatic pressure is being applied in the control channels thus, all the 


















Figure 5.9: ‘Closed’ microvalves in a working microfluidic chip. This image shows a partial 
view of the a rotary flow channel and its respective rotary pneumatic peristaltic micropump. In 
the image above, pneumatic pressure is being applied in the control channels thus, all the 
microvalves are in the ‘closed’ state i.e. they are not allowing fluid flow in the flow channel. As 
seen in the image above, all the microvalves have pinched off the flow channels, this is 
illustrated by the gaps in-between the flow channels in the region the microvalves are located. 
The loading of the control lines with fluid and the ‘opening’ and ‘closing’ of the valves was 





CHAPTER 6: CONCLUSION 
 
We have developed a simple, reliable and automated microfluidic fluid introduction system for off-
chip to on-chip fluid transport. The system makes use of relatively inexpensive hardware such as 
electrically actuated valves and microfluidic plugs. Based on the three versions of the automated 
systems developed, two showed to be more efficient than the manual set-up. The efficient versions 
were saving 60% - 68% of the time required to prepare the microfluidic system manually. 
The introduction of a graphical user operating system (MagicElf) and the use of microfluidic plugs 
has enhanced the increase in user-friendliness of microfluidic system operation. These systems limited 
human involvement to only microfluidic plug insertion into a chip and system operation via the 
MagicElf dashboard. During the development of this project, I was able to successfully learn the 
principles of microfluidics technology. I learnt how to fabricate microfluidic devices using 
photolithography and soft-lithography from concept drawings. I also developed programming skills in 
the LabVIEW programming environment. 
To a greater extent, the complete automation of the fluid transport, which was one of the aims of this 
project, has shown great potential as a one-of-a-kind solution to achieving the practicality of using 
microfluidic large scale integration platforms for point-of-care medical diagnostics. Going forward, 
the use of this system as proof of principle, improvements and optimizations is necessary to further 
develop this to the maturity required by international health standards. To compliment this proof of 
principle, we now aim to miniaturize the pressure and valve control module, such that the auto-












CHAPTER 7: FUTURE WORK 
 
Over the last decade, microdevices have generated vast interest in both academic and industrial 
laboratories [106].  Several challenges are yet to be overcome before these technologies can be 
translated into effective point-of-care medical diagnostic devices. A translation to point-of-care 
medical diagnostic devices requires the improvisation and optimization of all peripheral 
instrumentation associated with the system’s development and operation. In order to achieve this goal, 
it is critical to innovate. 
A study of African medical schools showed the extent at which innovation is emerging amongst 
academics [107]. The work described in this project is an example of innovation at play. This project 
has shown that it is possible to automate fluid transport off-chip to on-chip for microfluidic large scale 
integration systems. Moving forward, this project will involve optimizing the system and developing 
an enclosed, compact and portable versions of the system as a step towards decentralized health care 
and personalized medicine. 
From the previous work performed in this project, we have drawn up possible solutions to some of the 
problems identified in our first prototype. One such proposal is re-design of the punch that is used 
during the microfluidic chip fabrication process. We aim to re-design the punch such that precision is 
conserved between the punching process of microfluidic chip access ports and microfluidic plug 
development. Once precision is maintained, the separation on the microfluidic plug’s pins and the 
punched access ports on the microfluidic chip will be identical, thus removing the problem of 
microfluidic plug to chip misalignment. The new punch will be able to create 16 access ports at a time 
with the much needed accuracy. This punch will be highly suitable for use on the hybrid dual port 
microfluidic chip. The new proposed punch is a manual punch making it a cheaper solution to the 
existing problem than introducing an automated robotic punching system. The new punch will have 
an appearance as that shown in Figure 7.1. 
Apart from optimizing the automation protocol of the auto-loading system, we have proposed a new 
microfluidic chip design that we expect will increase the efficiency of the system by removing the 
introduced air more rapidly. This proposed device is exactly the same as the hybrid dual port 
microfluidic chip; instead of the 10 µm high and 100 µm wide ‘bridge’, the inter-connected access 
ports have a 500 µm high and 500 µm wide ‘bridge’ channel, this is shown in yellow in Figure 7.2. 






We expect that the increased dimensions of the bridge channel will facilitate faster removal of air in 
the system thus making it more efficient. In the future as well, we hope to replace the ‘elapsed time’ 
LabVIEW function incorporated into the operating system with flow sensors. Flow sensors will detect 
fluid flow at the fluid waste container and will send signals to the SD and SF valves to actuate 
accordingly.  
In brief, the plans for this project and the necessary steps to have it deployable in clinical settings are 
as follows: 
1. Finish the prototype development as proof of principle. This process will involve the 
miniaturization of the pressure and valve control module that shown in Figure 5.2 and 
extending this auto-loading system to also cater for the flow channel sample loading. At the 
end of this stage, we hope to have a compact and portable automation kit similar to a desktop 
computer casing that houses the computer motherboard and electronics. 
2. File for intellectual property and a patent protection (this is already underway). 
3. Seek investment for the reduction to practise phase. This will involve making the system 
foolproof such that it has a repeatable performance and is foolproof. This stage will also 
increase the user-friendliness of the system. 
4. Develop a prototype medical assay for POC testing (e.g. ELISA). 
5. Optimize the medical assay to medically accepted standards in small scale clinical studies. 
6. Seek approvals (e.g. ethics committees, national health councils etc.) for the system to be 
deployed into clinical practise. 
















Figure 7.1: Proposed new punch; (a) punch press at rest position; (b) punch press at 
cutting/punching position. The new punch design aims to conserve/maintain precision between 
the punching process of microfluidic chip access ports and microfluidic plug development. Once 
precision is maintained, the separation on the microfluidic plug’s pins and the punched access 
ports on the microfluidic chip will be identical, thus removing the problem of microfluidic plug 
to chip misalignment.  The new punch will be able to create 16 access ports at a time with the 
much needed accuracy. This punch will be highly suitable for use on the hybrid dual port 
microfluidic chip. The new proposed punch is a manual punch making it a cheaper solution to 




















Figure 7.2: Proposed new hybrid dual port microfluidic device geometry. This proposed device 
is exactly the same as the old hybrid dual port microfluidic chip; instead of the 10 µm high and 
100 µm wide ‘bridge’, the inter-connected access ports have a 500 µm high and 500 µm wide 
‘bridge’ channel, this is shown in yellow. We expect this new design to increase the efficiency of 













Appendix A: Single Port, Dual Port, Hybrid Dual Port 
Microfluidic Device Master Mold Protocol and Single Port 
and Dual Port PDMS Microfluidic Device Fabrication 
Protocol 
 
Rectangular channel: 10µm height 
1. SILANIZATION None 
2. SPIN Negative Photoresist: SU8-2010  
Spin at 3000rpm, 1min, ACL = 130rpm/sec 
3. PRE-EXPOSURE BAKE 650C            1min 
950C            2mins 
4. ALIGN [if necessary] 
5. EXPOSE 1.5secs 
6. POST-EXPOSURE 
BAKE 
650C            1mins 
950C            3mins  
7. DEVELOP Use Developer SU-8 Developer: 100% 
a. Develop for 1 – 2mins until a shiny surface 
engulfs the entire wafer 
b. Rinse in fresh SU-8 developer 
c. Spray with fresh SU-8 developer to flush out 
excess residue 
d. Dry gently with air gun  
8. PROFILE [if necessary] ~ Mold will be rectangular at this point 
9. ROUNDING STEP None 
10. PROFILE None 
11. HARD BAKE None 




Rounded channel: 10µm height 
1. SILANIZATION HMDS  for 2 mins  
2. SPIN Positive Photoresist: MAP 1275  
Spin at 1200rpm, 1min, ACL = 133rpm/sec 
3. PRE-EXPOSURE BAKE 950C            90secs 
4. ALIGN [if necessary] 




7. DEVELOP Use Developer ma-D 531: 100% 
e. Develop for 3 – 5mins until a shiny surface 
engulfs the entire wafer 
f. Rinse in fresh water 
g. Spray with fresh water to flush out excess 
developer 
h. Dry gently with air gun  
8. PROFILE [if necessary] ~ Mold will be rectangular at this point 
9. ROUNDING STEP Leave the rectangular mold overnight 
Mold Reflow:  
650C  3mins 
                        1150C      15mins 
10. PROFILE Profile to ensure rounded cross-section. Mold will be 
rounded at this point. Single shiny line will be visible 
11. HARD BAKE [If layering on top]: 
a. Set oven to 1200C 
b. Place mold in oven at 1200C 
c. Ramp oven to 1800C 
d. Leave in the oven for 1hr at 1800C 
e. Ramp down oven to 1200C 







Single Port and Dual Port PDMS Microfluidic Device Fabrication Protocol 
 
1. Cleaning molds: 
 
 Wafers are to be silanized using TCMS vapours for 2 minutes in air tight container. 
 
2. Flow layer PDMS casting: 
 
 Prepare an 80grams:16grams PDMS mixture (5:1 elastomer base to cross-linker 
base) in a plastic cup. This gives a 4 – 5 mm thick layer. 
 Perform a weight measurement of the PDMS containing cup and the mixer cup 
holder is done and the correct measurement is entered into the planetary centrifugal 
mixer machine for mixing. 
 Planetary centrifugal mixer settings: Speed – 2200 rpm; Mixing time – 5 minutes; 
Defoaming time – 5 minutes. 
 After PDMS mixing, pour the PDMS mixture onto the flow layer master mold which 
are in an aluminium foil covered petri dish. 
 Place the flow layer master molds in a desiccator under vacuum for de-bubbling until 
all bubbles have risen to the surface of the PDMS. 
 Remove the bubbles in the area on of concern (i.e. device pattern) using a spreader.  
 Repeat the de-bubbling and bubble removal step until no bubbles are left covering 
the pattern. 
 Place the flow layer containing petri dish in the oven for 40 minutes at 80 °C. 
 
3. Control layer PDMS casting and glass slide/ cover slip coating: 
 
 Prepare a 20grams:1grams PDMS mixture (20:1 elastomer base to cross-linker base) 
in a plastic cup.  
 Perform a weight measurement of the PDMS containing cup and the mixer cup 
holder is done and the correct measurement is entered into the planetary centrifugal 




 Planetary centrifugal mixer settings: Speed – 2200 rpm; Mixing time – 5 minutes; 
De-foaming time – 5 minutes. 
 After PDMS mixing, spin coat the control layer master mold and the microscope 
glass slide in a spin coater. 
 Spin coater settings: Speed – 1800 rpm; Time – 1 minute; Acceleration – 
500rpm/second. 
 After spin coating, let stand for 5 minutes then place the spin-coated components i.e. 




4. Alignment:  
 
 After the baking of the flow layer master mold is complete. 
 Peel off the PDMS flow layer from the master mold and cut to size using a 
razorblade or scalpel. 
 Create flow channel access ports by punching the port patterns on the PDMS layer 
using a punch press. 
 Align the flow layer PDMS layer onto the PDMS spin-coated and soft-baked control 
layer master mold. This can be aided by using a microscope. 
 
5. PDMS bonding: 
 
 After the alignment procedure is complete. 
 Place the aligned device in oven for 40 minutes at 80 °C. 
 After the baking is complete. 
 Cut and peel off the bonded device off the control layer mold. 
 Create control channel access ports by punching the port patterns on the PDMS layer 
using a punch press. 
 
6. Substrate bonding: 
 




 Place the microfluidic device in an oven at 80 °C for several hours (usually 9 – 12 
hours) to allowing the PDMS structures control layer to bond to the substrate. 






















Appendix B: Hybrid Dual Port PDMS Microfluidic Device 
Fabrication Protocol 
 
1. Cleaning molds: 
 
 Wafers are to be silanized using TCMS vapours for 2 minutes in air tight container. 
 
2. Control layer PDMS casting: 
 
 Prepare an 80grams:16grams PDMS mixture (5:1 elastomer base to cross-linker 
base) in a plastic cup. This gives a 4 – 5 mm thick layer. 
 Perform a weight measurement of the PDMS containing cup and the mixer cup 
holder is done and the correct measurement is entered into the planetary centrifugal 
mixer machine for mixing. 
 Planetary centrifugal mixer settings: Speed – 2200 rpm; Mixing time – 5 minutes; 
Defoaming time – 5 minutes. 
 After PDMS mixing, pour the PDMS mixture onto the control layer master mold 
which are in an aluminium foil covered petri dish. 
 Place the control layer master molds in a desiccator under vacuum for de-bubbling 
until all bubbles have risen to the surface of the PDMS. 
 Remove the bubbles in the area on of concern (i.e. device pattern) using a spreader.  
 Repeat the de-bubbling and bubble removal step until no bubbles are left covering 
the pattern. 
 Place the control layer containing petri dish in the oven for 40 minutes at 80 °C. 
 
3. Flow layer PDMS casting and glass slide/ cover slip coating: 
 
 Prepare a 20grams:1grams PDMS mixture (20:1 elastomer base to cross-linker base) 
in a plastic cup.  
 Perform a weight measurement of the PDMS containing cup and the mixer cup 
holder is done and the correct measurement is entered into the planetary centrifugal 




 Planetary centrifugal mixer settings: Speed – 2200 rpm; Mixing time – 5 minutes; 
De-foaming time – 5 minutes. 
 After PDMS mixing, spin coat the flow layer master mold and the microscope glass 
slide in a spin coater. 
 Spin coater settings: Speed – 1800 rpm; Time – 1 minute; Acceleration – 
500rpm/second. 
 After spin coating, let stand for 5 minutes then place the spin-coated components i.e. 




4. Alignment:  
 
 After the baking of the control layer master mold is complete. 
 Peel off the PDMS control layer from the master mold and cut to size using a 
razorblade or scalpel. 
 Create control channel access ports by punching the port patterns on the PDMS layer 
using a punch press. 
 Align the control layer PDMS layer onto the PDMS spin-coated and soft-baked flow 
layer master mold. This can be aided by using a microscope. 
 
5. PDMS bonding: 
 
 After the alignment procedure is complete. 
 Place the aligned device in oven for 40 minutes at 80 °C. 
 After the baking is complete. 
 Cut and peel off the bonded device off the flow layer mold. 
 Create flow channel access ports by punching the port patterns on the PDMS layer 
using a punch press. 
 
6. Substrate bonding: 
 




 Place the microfluidic device in an oven at 80 °C for several hours (usually 9 – 12 
hours) to allowing the PDMS structures control layer to bond to the substrate. 
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